US20140186470A1 - Compositions - Google Patents

Compositions Download PDF

Info

Publication number
US20140186470A1
US20140186470A1 US14/202,098 US201414202098A US2014186470A1 US 20140186470 A1 US20140186470 A1 US 20140186470A1 US 201414202098 A US201414202098 A US 201414202098A US 2014186470 A1 US2014186470 A1 US 2014186470A1
Authority
US
United States
Prior art keywords
per litre
solution
ascorbate
colon cleansing
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/202,098
Other languages
English (en)
Inventor
Lucy Clayton
Alasdair Cockett
Mark Christodoulou
Ian Davidson
Lynn Farrag
Marc Halphen
Leighton Jones
Vanik Petrossian
Peter Stein
David Tisi
Alex Ungar
Jeffrey Worthington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norgine BV
Original Assignee
Norgine BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49165735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140186470(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norgine BV filed Critical Norgine BV
Priority to US14/202,098 priority Critical patent/US20140186470A1/en
Assigned to NORGINE BV reassignment NORGINE BV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIDSON, IAN, FARRAG, Lynn, JONES, LEIGHTON, HALPHEN, MARC, STEIN, PETER, CHRISTODOULOU, Mark, CLAYTON, Lucy, COCKETT, ALASDAIR, UNGAR, ALEX, PETROSSIAN, VANIK, TISI, DAVID, WORTHINGTON, Jeffrey
Publication of US20140186470A1 publication Critical patent/US20140186470A1/en
Priority to SG10201807427RA priority patent/SG10201807427RA/en
Priority to EP20189946.5A priority patent/EP3777850B1/en
Priority to PL20189946.5T priority patent/PL3777850T3/pl
Priority to AU2015228962A priority patent/AU2015228962B2/en
Priority to SG11201606834QA priority patent/SG11201606834QA/en
Priority to NZ723017A priority patent/NZ723017B2/en
Priority to MYPI2016703268A priority patent/MY188550A/en
Priority to PT201899465T priority patent/PT3777850T/pt
Priority to MX2016011256A priority patent/MX2016011256A/es
Priority to CN201580013447.5A priority patent/CN106102738A/zh
Priority to UAA201610268A priority patent/UA123659C2/uk
Priority to PCT/EP2015/054856 priority patent/WO2015135880A1/en
Priority to DK20189946.5T priority patent/DK3777850T3/da
Priority to CA2942089A priority patent/CA2942089C/en
Priority to BR112016019914A priority patent/BR112016019914A8/pt
Priority to CN202210809414.3A priority patent/CN115154464A/zh
Priority to MX2021005225A priority patent/MX2021005225A/es
Priority to ES20189946T priority patent/ES2928719T3/es
Priority to EP15709665.2A priority patent/EP3116494B8/en
Priority to EA201600639A priority patent/EA037891B1/ru
Priority to ES15709665T priority patent/ES2831412T3/es
Priority to KR1020167027883A priority patent/KR102234803B1/ko
Priority to US14/954,290 priority patent/US20160184263A1/en
Priority to IL247170A priority patent/IL247170B/en
Priority to ZA2016/05592A priority patent/ZA201605592B/en
Priority to US15/605,617 priority patent/US10918723B2/en
Assigned to NORGINE BV reassignment NORGINE BV CHANGE OF ADDRESS Assignors: NORGINE BV
Priority to IL274374A priority patent/IL274374A/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a method of cleansing the colon using colon cleansing solutions, and compositions and kits associated therewith.
  • Colon cleansing compositions are also known as lavage solutions, bowel cleansers, purgatives or colonic evacuants.
  • Colon or bowel cleansing is important before numerous surgical or diagnostic procedures, including colonoscopy, barium enema examination, sigmoidoscopy and colon surgery. Such procedures are often carried out on an outpatient basis and thus it is desirable that the colon cleansing be carried out by the patient at home, prior to arrival at the hospital or surgery where the procedure is to take place. It is therefore important that patient compliance is good without medical supervision if satisfactory colon cleansing is to be achieved prior to the procedure.
  • Intestinal lavage in which a large volume of an aqueous electrolyte solution containing sodium sulphate and polyethylene glycol is ingested, is one of the most common methods for colon cleansing.
  • These osmotically active agents are non-absorbable or only poorly absorbable and thus retain water in the bowel, resulting in copious diarrhea and cleansing of the colon.
  • compositions For effective cleansing, many of these compositions must be ingested in quantities of between 2 to 4 litres.
  • the unpleasant taste of these compositions combined with the large volumes required to be ingested often contributes to nausea or vomiting, resulting in poor patient compliance and failure to consume the full volume of solution.
  • Poor patient compliance can lead to inadequate preparation of the colon which can, in turn, lead to cancellation or repetition of the colonoscopy or other procedure becoming necessary or, worse, non-detection of lesions or polyps indicative of cancer risk.
  • a number of improved colon cleansing compositions are described in WO 2004/037292.
  • a colon cleansing composition according to WO 2004/037292 that comprises polyethylene glycol 3350, sodium sulphate, an ascorbate component, electrolytes, sweetener and flavouring is commercialised as a powder for oral solution under the tradename MOVIPREP® (registered trademark of Velinor AG, a member of the Norgine group of companies).
  • MOVIPREP® registered trademark of Velinor AG, a member of the Norgine group of companies.
  • the MOVIPREP solution is effective despite being taken in a substantially lower volume than other colon cleansing solutions. Typically, only 2 litres of the solution need to be taken by an adult patient (along with additional clear fluid), a significant benefit when compared to taking 4 litres of previous solutions.
  • SUPRPEP contains 17.5 g sodium sulphate, 3.13 g potassium sulphate and 1.6 g magnesium sulphate and it is taken in a volume of 16 US fluid ounces (473 ml). A treatment comprises two doses of that solution.
  • the MOVIPREP solution mentioned above may be taken (optionally with additional clear liquids also being taken) in the evening before the examination or procedure, or the MOVIPREP solution may be taken in a “split-dose” regimen, with approximately half of the cleansing solution being taken the evening before the examination or procedure (“first dose”), and the remainder being taken the following morning (“second dose”).
  • first dose approximately half of the cleansing solution being taken the evening before the examination or procedure
  • second dose approximately half of the cleansing solution
  • second dose approximately half of the cleansing solution being taken the following morning
  • the SUPREP product mentioned above is recommended to be taken as first dose in the evening before the examination procedure, accompanied by an additional quart of water (946 ml), followed by a second dose in the morning of the procedure.
  • lavage solutions An alternative to the lavage solutions described above is provided by low volume hypertonic salt solutions.
  • Examples include Fleet's phosphosoda product and sodium picosulphate solutions. These are very concentrated salt solutions and patients need ingest only a small volume of them (around 100 ml). However, these products have been associated with a hypo-osmolar state and electrolyte imbalance in subjects, particularly hyponatremia. They are particularly contra-indicated in subjects with kidney problems.
  • the invention provides, in a first aspect, a colon cleansing solution comprising:
  • the solution of the invention has a surprisingly palatable taste.
  • the particular ratio of ascorbic acid to salt of ascorbic acid enables the salty taste of ascorbate salt to be balanced by sourness from acid to a palatable extent, whilst at the same time not reducing the osmotic effect of the ascorbate component or making the solution too sour.
  • the solution of the invention is highly effective as a colon cleansing solution when ingested in a lower volume than many prior art solutions, and it has a good tolerability profile.
  • the solutions of the invention are aqueous solutions.
  • the mixture of ascorbic acid and one or more salts of ascorbic acid will, for convenience, be referred to herein as the “ascorbate component”.
  • Suitable salts of ascorbic acid include alkali metal salts and alkaline earth metal salts.
  • a salt may be selected from sodium, potassium, magnesium and calcium salts.
  • preferred salts of ascorbic acid include sodium ascorbate, potassium ascorbate, magnesium ascorbate and calcium ascorbate.
  • the molar ratio between (i) the ascorbic acid and (ii) the one or more salts of ascorbic acid is the molar ratio of the ascorbate moieties; for example, magnesium ascorbate comprises two moles of ascorbate per mole of salt; for the ratio purposes, it is the number of moles of ascorbate that is counted.
  • Particularly preferred salts of ascorbic acid are magnesium ascorbate and sodium ascorbate, for example sodium ascorbate.
  • the solution of the invention comprises ascorbic acid and sodium ascorbate (and preferably no further ascorbate).
  • the molar ratio of the components (i) and (ii) is from 1:4.75 to 1:6.75; more preferably from 1:5.0 to 1:6.0; for example from 1:5.40 to 1:5.80; for example 15:85.
  • the solution of the invention preferably comprises ascorbate anion in a concentration of: 300-700 mmol per litre, for example 350-650 mmol per litre, for example 450-600 mmol per litre.
  • a solution of the invention may comprise 50 to 140 g/litre of ascorbate component.
  • a solution of the invention comprises 60 to 140 g/litre, for example 80 to 130 g/litre, for example 80 to 120 g/litre, for example 100 to 120 g/litre of ascorbate component.
  • Ascorbic acid has a molecular weight of 176 g/mol.
  • Sodium ascorbate has a molecular weight of 198 g/mol.
  • a mixture of ascorbic acid and sodium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 has ascorbic acid and sodium ascorbate present in a weight ratio of 1:5.063 to 1:7.875.
  • the weight ratio can be 1:5.344 to 1:7.594; more preferably from 1:5.625 to 1:6.75; for example from 1:6.075 to 1:6.525, for example 1:6.38.
  • a solution of the invention may comprise from 6 to 25 g/litre of ascorbic acid and 50 to 120 g/litre of sodium ascorbate, for example 12 to 20 g/litre of ascorbic acid and 80 to 120 g/litre of sodium ascorbate (with the ratio between them being as mentioned above).
  • a solution of the invention may comprise from 14 to 16 g g/litre of ascorbic acid and 92 to 100 g/litre of sodium ascorbate.
  • Potassium ascorbate has a molecular weight of 214 g/mol. Accordingly, a mixture of ascorbic acid and potassium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 has ascorbic acid and potassium ascorbate present in a weight ratio of 1:5.471 to 1:8.511.
  • the weight ratio can be 1:5.776 to 1:8.208; more preferably from 1:6.080 to 1:7.295; for example from 1:6.565 to 1:7.052, for example 1:6.896.
  • a solution of the invention may comprise from 6 to 25 g/litre of ascorbic acid and 50 to 125 g/litre of potassium ascorbate, for example 6 to 12 g/litre of ascorbic acid and 80 to 120 g/litre of potassium ascorbate.
  • Magnesium ascorbate has a molecular weight of 374.5 g/mol and each mole of magnesium ascorbate provides two moles of ascorbate. Accordingly, a mixture of ascorbic acid and magnesium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 (of ascorbate anion) has ascorbic acid and magnesium ascorbate present in a weight ratio of 1:4.794 to 1:7.457.
  • the weight ratio can be 1:5.061 to 1:7.191; more preferably from 1:5.326 to 1:6.397 for example from 1:5.753 to 1:6.179, for example 1:6.042.
  • a solution of the invention may comprise from 6 to 25 g/litre of ascorbic acid and 45 to 120 g/litre of magnesium ascorbate, for example 6 to 12 g/litre of ascorbic acid and 75 to 115 g/litre of magnesium ascorbate.
  • ascorbate anion may be protonated and thus exist as free ascorbic acid in solution. At the pH of solutions that would typically be administered, only a very minor proportion of ascorbate is protonated. In calculations of concentrations of “ascorbate anion” herein, the concentration of “ascorbate anion” is taken as the total concentration of all ascorbate anion present, including the proportion that is protonated.
  • the cleansing solution comprises polyethylene glycol.
  • the polyethylene glycol (PEG) may, for example, have an average molecular weight of 2000 to 8000, for example 2500 to 4500 Da, for example 2680 to 4020 Da, for example 3000 to 4000 Da.
  • the PEG may be PEG 3350 or PEG 4000 as defined in national pharmacopeias.
  • PEG8000 may also be used.
  • suitable PEGs recognized in some national pharmacopeias include Macrogols, for example Macrogol 3350 or Macrogol 4000.
  • the cleansing solution comprises 10 to 200 g per litre of PEG.
  • the solution of the invention comprises 20 to 160 g per litre of PEG, more preferably 40 to 120 g per litre, for example 60 to 100 g per litre, for example 75 to 85 g per litre, for example 80 g per litre.
  • the cleansing solution may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the cleansing solution may comprise one or more electrolytes. Electrolytes include salts of sodium, potassium, calcium and magnesium, particularly sodium and potassium; and salts of chloride, iodide, bicarbonate and carbonate, particularly chloride. Preferred electrolytes are sodium chloride and potassium chloride. In an embodiment, the solution is essentially free from sodium bicarbonate, for example essentially free from any bicarbonate.
  • the solution of the invention may comprise sodium chloride at a concentration of 1 to 10 g per litre.
  • sodium chloride may be present at a concentration of 3 to 8 g per litre, for example 4 to 7 g per litre; for example 6.0 to 6.8 g per litre; for example 5.6 g per litre or 6.4 g per litre.
  • the solution of the invention may comprise potassium chloride at a concentration of 1 to 10 g per litre.
  • potassium chloride may be present at a concentration of 1 to 7 g per litre, for example 1.5 to 5 g per litre, for example 1.5 to 3 g per litre, for example 2.0 to 2.8 g per litre; for example 2.4 g per litre or 2.6 g per litre.
  • the solution of the invention comprises sodium chloride and potassium chloride. They can be present in the amounts mentioned immediately above.
  • sodium chloride may be present at a concentration of 4 to 7 g per litre and potassium chloride may be present at a concentration of 1.5 to 3 g per litre.
  • the cleansing solution may comprise one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof (herein referred to as a “sulphate component”).
  • An alkali metal or alkaline earth metal sulphate may, for example, be selected from sodium sulphate, potassium sulphate and magnesium sulphate.
  • the solution of the invention may comprise more than one of sodium sulphate, potassium sulphate and magnesium sulphate, for example all three.
  • the sulphate component is or includes sodium sulphate.
  • the solution of the invention may comprise a sulphate component at a concentration of 2 to 20 g per litre, for example 5 to 15 g per litre, for example 8 to 15 g per litre, for example 10 to 14 g per litre, for example 12 g per litre.
  • the one or more sulphate salts may be provided in any pharmaceutically acceptable form: they may each be anhydrous, or be in a hydrated form.
  • the weights mentioned herein refer to the weight of the sulphate salt excluding any water of hydration.
  • the solution of the invention does not comprise a sulphate component; that is to say that the solution is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • the term “essentially free from” a component means that the named component is present at a level that is below the level that has any functional effect in the solution of the invention in its use; for example, the named component may be at a level that is below the level at which it has a measurable clinical effect. For example, it may mean that the component is present at a level of less than 0.1 g per litre; for example less than 0.03 g per litre; for example less than 0.01 g per litre, for example less than 0.003 g per litre, for example less than 0.001 g per litre.
  • the quantities of the individual components recited do not include any solutes that may be present in the water used to prepare the solutions, for example, in hard water areas there may be significant amounts of Ca 2+ and Mg 2+ carbonates, bicarbonates or sulphates present in tap water.
  • the cleansing solution preferably includes a flavouring agent.
  • a flavouring agent for use in compositions of the invention should preferably mask saltiness, be relatively sweet but not excessively so, and be stable in the composition.
  • a flavouring agent makes the solutions more palatable and thus aids patient compliance.
  • Preferred flavourings include lemon e.g. Ungerer Lemon (available from Ungerer Limited, Sealand Road, Chester, England CH1 4LP), strawberry e.g. Ungerer Strawberry, grapefruit e.g. Ungerer Grapefruit flavouring powder, blackcurrant e.g. Ungerer Blackcurrant, pineapple e.g. IFF (International Flavours and Fragrances) Pineapple flavouring powder, orange eg Firmenich Orange, vanilla/lemon and lime e.g.
  • flavouring agent is alcohol-free.
  • the amount of flavouring agent required depends on the nature and strength of the flavouring in question. Typically, it is 0.05 to 4.5 g per litre, for example 0.05 to 2.0 g per litre, for example 0.2 to 1.8 g per litre, for example 1.0 to 1.8 g per litre, for example 3.0 to 4.5 g per litre, for example 0.3 g per litre or 1.2 g per litre, for example 3.2 or 4.2 g per litre.
  • the cleansing solution preferably includes a sweetener.
  • Sugar-based sweeteners are generally not suited for colon cleansing compositions because the delivery of unabsorbed sugars to the colon provides a substrate for bacteria. Such sugars may be metabolised by the bacteria to form explosive gases such as hydrogen and methane. The presence of explosive gases in the colon can be highly dangerous when electrical apparatus is to be used during colonoscopy or other procedures.
  • Preferred sweeteners include aspartame, acesulfame potassium (acesulfame K), sucralose and saccharine, and/or combinations thereof.
  • compositions of the invention may comprise one or both of aspartame and acesulfame potassium (acesulfame K).
  • compositions of the invention may comprise one or both of sucralose and acesulfame potassium (acesulfame K).
  • the solution comprises aspartame or sucralose, for example aspartame.
  • compositions of the invention can be essentially free from added sweeteners, for example to minimize the number of different components in the compositions.
  • a souring agent for example citric acid
  • a souring agent is a component that imparts a sourness to a composition.
  • Other souring agents include malic acid, acetic acid, tartaric acid, gluconodeltalactone, phosphoric acid, succinic acid, phytic acid, lactic acid or salts thereof.
  • the souring agent (for example citric acid) may be provided in an encapsulated form.
  • the encapsulation provides a coating that isolates the souring agent from other components and from air and moisture prior to its use.
  • the encapsulation may be with a water-soluble coating.
  • the amount of sweetener required depends on the nature and strength of the sweetener being considered. Typically, it is 0.10 to 4 g per litre.
  • the sweetener may be aspartame at 0.5 to 4 g per litre, for example 2.5 to 4.0 g per litre, for example 3.0 g per litre, for example 3.86 g per litre.
  • Those quantities of aspartame are particularly suitable when used with orange flavouring, for example orange flavouring at 0.2 to 1.8 g per litre, for example 1.0 to 1.8 g per litre, for example 0.3 g per litre, 0.875 g per litre or 1.2 g per litre.
  • the sweetener may be aspartame at 1.0 to 2.5 g per litre, for example 1.5 to 2.0 g per litre, for example 1.75 g per litre.
  • the invention thus provides a colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • the invention provides a colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be present in the concentrations described above.
  • Each of e) and f) may be as described above and/or be in the concentrations described above.
  • the invention provides a colon cleansing solution comprising:
  • flavouring agents e) one or more flavouring agents
  • one or more components of c), d) (when present), e) and f) are present in the solution of the invention.
  • some or all of components c), d) (when present), e) and f) may be provided separately from the solution of the invention, for example in a tablet or capsule.
  • components c) and d) may be provided in tablet form.
  • the solution of the invention may comprise a) the ascorbate component and b) PEG, and optional flavouring and sweetener (e) and f)), and a tablet or capsule may comprise c) the one or more electrolytes (optionally with d), the one or more alkali metal or alkaline earth metal sulphates), again with optional flavouring and sweetener (e) and f).
  • the flavouring and sweeteners need not be the same in the tablet or capsule as in the solution.
  • the invention provides a colon cleansing solution comprising: a)
  • flavouring agents e) one or more flavouring agents
  • the solution of the invention consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the solution of the invention may, for example, not contain any sulphate.
  • the invention provides a colon cleansing solution consisting essentially of: a)
  • flavouring agents e) one or more flavouring agents
  • the invention provides a colon cleansing solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 1.20 g per litre orange flavour and 3.86 g per litre aspartame.
  • the flavouring and sweetener may be 3.20 g per litre citrus flavour and 1.75 g per litre aspartame.
  • the flavouring and sweetener may be 4.20 g per litre orange grapefruit flavour and 1.75 g per litre aspartame.
  • the colon cleansing solution is hyper-osmotic. That is to say that it has a higher osmotic strength than blood in the human body. It may, for example have a measured osmolality in the range 500 to 2000 mOsmol/kg.
  • the osmolality may be in the range 700 to 1800 mOsmol/kg.
  • the solutes in 500 ml of the solution of the invention may have a measured V(350) value of from 1000 to 2000 ml, for example from 1300 to 2000 ml, for example from 1400 to 1900 ml, and be in a volume of 400 to 600 ml, for example 500 ml.
  • the V(350) value is the volume of water that is required to provide a solution with an osmolality of 350 mOsmol/kg, the total volume being the final volume after a volume water has been added to a solution having an initial volume.
  • Osmolality can be measured in various ways. In general, either freezing point depression or vapour-pressure alteration is used. For example, an Advanced Instruments, Inc Model 3250 osmometer (a freezing point depression device) can be used. Vapour pressure measurement can also be used, for example using an ELITech Group Vapro 5600 device. Osmolality values cited herein are preferably taken to be values measured using a freezing point depression osmometer, for example using an Advanced Instruments, Inc Model 3250 osmometer following standard operating procedure.
  • the invention provides a colon cleansing solution comprising:
  • 500 ml of the solution may have a V(350) osmolality value of from 1500 to 2100 ml, for example from 1700 to 2000 ml, for example from 1800 to 1900 ml.
  • solutions of the invention may include one or more additional optional components:
  • a laxative may be present, for example a stimulant laxative.
  • a stimulant laxative for example, bisacodyl, castor oil, senna or bisoxatin may be used.
  • An example of a colon cleansing solution containing bisoxatin is known from WO2013001315.
  • contrast media can be included in a solution of the invention.
  • contrast media include barium or iodine products, diatrizoate (marketed, for example, as HYPAQUE 50), metrizoate (marketed, for example, as ISOPAQUE 370), ioxalgate (marketed, for example, as HEXABRIX), iopamidol (marketed, for example, as ISOVUE 370 ), iohexyl (marketed, for example, as OMNIPAQUE 350), ioxilan (marketed, for example, as OXILAN 350), iopramide (marketed, for example, as ULTRAVIST 370), iodixanol (marketed, for example, as VISIPAQUE 320) and/or a diatrizoic acid or its anionic form diatrizoate (also known as amidotrizoic acid, or 3,5-diacetamido-2,4,6-triiodobenzoic acid; marketed,
  • one or more dyes or stains that are markers of particular mucosal pathology can be included in a solution of the invention. Stains may be selective. For example, hexaminolevulinate may be used, for example as its HCl salt (marketed as CYSVIEW). Other markers of colonic or rectal mucosal pathology can be used. For example methylene blue, which can stain the normal mucosa yet polyps do not stain and become more clearly visible.
  • dyes and stains include: Curcumin, Riboflavin, Riboflavin-5′-phosphate, Tartrazine, Quinoline Yellow, Sunset Yellow, FCF Orange, Yellow S, Cochineal, Carminic acid, Carmines, Azorubine, Carmoisine, Ponceau 4R, Cochineal Red A, Allura Red AC, Patent Blu EV, Indigotine, Indigo carmine, Brilliant Blue FCF, Chlorophylls and chlorophyllins, Copper complexes of chlorophylls and chlorophyllins, Green S, Plain caramel, Brilliant Black BN, Black PN, Vegetable carbon, Brown HT, Carotenes, Lutein, Beetroot Red, betanin, Anthocyanins, Calcium carbonate, Titanium dioxide, Iron oxides and hydroxides, Amaranth, Brown F, Erythrosine, Lithol Rubine B and/or
  • Red 2G Further dyes and stains that may be mentioned include: acid fuchsine, Alba red, Alizarin cyanine green F, Alizurol purple S5, Allura Red AC, Alphazurine FGBrilliant lake red R, Dibromofluorescein, Diiodofluorescein, Eosine, Erythrosine yellowish Na, Fast green FCF, Flaming red, Fluorescein, Helindone pink CN, Indanthrene blue, Lake bordeaux B, Lithol rubin B Ca, Naphthol yellow 5 , Orange II, Phloxine B, Ponceau 5 ⁇ , Pyranine concentrated, Quinizarinegreen 5S, Tetrabromo-fluorescein, Tetrachlorotetrabromo fluorescein, Toney red, Uranine, Alcian Blue, Anazolene Sodium, Brilliant Green, Cantaxanthin, Carthamin, Citrus Red 2, Evan's Blue, Fast Green FCF, lndocyanine Green, Methyl Blue, Methylene
  • the solution of the invention may be used in conjunction with (e.g., simultaneously, before or after) administration of a dye or stain.
  • a dye or a stain may be provided in slow or delayed release form, for example delayed release methylene blue (for example MMX format of colonic-released methylene blue developed by Cosmo Pharmaceuticals, Lainate, Italy) may be mentioned.
  • a surfactant may be included in a solution of the invention.
  • a surfactant may assist in avoiding the persistence of bubbles in the colon. Such bubbles can interfere with the visualisation of features of the colon during colonoscopy.
  • Surfactants that may be mentioned include simethicone (or any mixture of polydimethylsiloxane and silica gel), dimethicone. Colon cleansing solutions containing simethicone are described in WO2009052256.
  • a lubricant may be included in a solution of the invention.
  • the inclusion of a lubricant can help with a colonoscope insertion and facilitation within the performance of the colonoscopy.
  • Suitable lubricants include glycerol or silicone.
  • a biofilm disrupting compound may be included in a solution of the invention.
  • a compound that disrupts biofilms may assist in separating an adherent polysaccharide DNA-containing layer, the so-called “biofilm” from the colonic mucosa. Removal of that layer may assist in achieving a cleaner and/or more easily visualized or stained mucosa.
  • Biofilm-disrupting components or agents that may be mentioned include enzymes such as deoxyribonuclease (DNase), N-acetylcysteine, alginate lyase, glycoside hydrolase dispersin B; Quorum-sensing inhibitors e.g., ribonucleic acid III inhibiting peptide, Salvadora persica extracts, Competence-stimulating peptide, Patulin and penicillic acid; peptides—cathelicidin-derived peptides, small lytic peptide, PTP-7 (a small lytic peptide, see e.g., haridia (201 1) J. Microbiol.
  • DNase deoxyribonuclease
  • N-acetylcysteine alginate lyase
  • glycoside hydrolase dispersin B glycoside hydrolase dispersin B
  • Quorum-sensing inhibitors e.g., ribonucleic acid III inhibiting peptid
  • the solution of the invention may be used in conjunction with (e.g., simultaneously, before or after) administration of a biofilm-disrupting compound.
  • a biofilm-disrupting compound may be administered towards the end of ingestion of the solution of the invention, or shortly after completion of ingestion of the solution of the invention, so as to disrupt the biofilm most just before the colonoscopy.
  • Some of the osmotic load of the solution of the invention may be provided by an organic acid or salts of an organic acid other than ascorbic acid.
  • citric acid and/or salts thereof may replace some or all of the ascorbate in solutions of the invention.
  • ascorbic acid may be replaced with citric acid.
  • a salt of ascorbate may be replaced with the salt of citrate.
  • Sodium citrate, potassium citrate and magnesium citrate are particularly preferred.
  • the solutions of the invention find use in cleansing the colon or bowel. They are also useful in the treatment of fecal impaction or constipation.
  • a subject When carrying out a colon or bowel cleansing treatment, a subject typically takes a single dose or a split dose of cleansing solution.
  • a split-dose treatment typically two doses are taken separated by a time interval, for example an overnight interval.
  • two doses may be taken on the same day, for example during the day before a diagnostic, therapeutic or surgical procedure, or during the day of a diagnostic, therapeutic or surgical procedure.
  • Each dose in a split dose treatment is smaller than the dose in the single dose treatment.
  • the two doses may each have the same composition, or they may be different.
  • the solution of the invention may be ingested in a volume of 700 to 1500 ml.
  • the subject may ingest from 750 ml to 1300 ml of the solution, for example 800 to 1200 ml, for example 900 to 1100 ml, for example 1000 ml.
  • 33 or 34 US fluid ounces may be ingested.
  • the subject may ingest some additional clear fluid.
  • the additional clear fluid may be ingested after ingesting the solution of the invention.
  • the additional clear fluid may be co-administered with the intake of the solution of the invention.
  • co-administered is meant the coordinated ingestion of a solution of the invention with additional clear fluid; that is to say that the subject ingests some of the solution of the invention but not necessarily the whole dose, then some additional clear fluid and then more solution of the invention.
  • the solution of the invention may be taken as one or both of the doses, each dose having a volume of 200 to 1000 ml.
  • the subject may ingest (as one of the doses) 300 ml to 1000 ml of the solution, for example 300 ml to 900 ml, for example 300 ml to 800 ml, for example 400 ml to 700 ml, for example 400 to 600 ml, for example 450 to 550 ml, for example 500 ml.
  • 300 ml to 1000 ml of the solution for example 300 ml to 900 ml, for example 300 ml to 800 ml, for example 400 ml to 700 ml, for example 400 to 600 ml, for example 450 to 550 ml, for example 500 ml.
  • 16 or 17 US fluid ounces may be ingested.
  • the combined volume of the first and second doses is preferably less than 2 litres. Preferably, it is 1750 ml or less, for example 1500 ml or less, for example 1250 ml or less. For most adult subjects, a combined volume of more than 500 ml is used, for example more than 750 ml. For example, a combined volume of from 500 ml to 1750 ml is used, for example from 750 ml to 1500 ml, for example from 1000 ml to 1500 ml, for example 1000 ml or 1250 ml.
  • the first dose may have a volume of 500 ml (for example a volume of 16 or 17 US fluid ounces) or 750 ml (for example a volume of 25 or 26 US fluid ounces) and the second dose may have a volume of 500 ml (for example a volume of 16 or 17 US fluid ounces).
  • the subject may ingest some additional clear fluid with each or either dose of colon cleansing solution.
  • the additional clear fluid may be taken after ingesting a dose of the solution.
  • the additional clear fluid may be co-administered with the intake of a dose of the solution of the invention; that is to say that the subject ingests some of the solution of the invention but not necessarily the whole dose, then some clear fluid and then more solution of the invention.
  • the time interval between ingesting the first dose and ingesting the second dose.
  • the time interval is at least 4 hours, for example 6 hours or more, for example 8 hours or more.
  • the time interval is less than 15 hours.
  • the time interval between starting to take the first dose and starting to take the second dose may be, for example, the time between an evening and the following morning, for example 12 to 16 hours, for example 14 hours.
  • the subject may sleep (for example overnight) between taking the first and second doses.
  • the time interval between ingesting the first dose and ingesting the second dose can be at least 10 minutes, for example from 10 minutes to 4 hours, for example from 30 minutes to 4 hours, for example from 30 minutes to two hours.
  • the subject may ingest the first and second colon cleansing doses the evening before a surgical, therapeutic or diagnostic procedure (hereinafter “procedure”).
  • the subject may ingest the first and second colon cleansing doses on the day of a procedure.
  • the time interval between ingesting the first solution and ingesting the second solution can be determined by the time it takes for the subject to experience a bowel movement.
  • the subject takes the second dose when the first bowel movement has occurred after completing ingestion of the first solution.
  • the subject ingests the second dose when the first bowel movement has occurred even if ingestion of the first dose is not complete.
  • two doses may be taken on the same day, for example during the day before a procedure, or during the day of a procedure.
  • the overall process is thus typically the sequence:
  • t 0: the subject takes a first dose of cleansing solution over a time t(d1), optionally followed by additional clear fluid over a time t(cf1);
  • Each dose of cleansing solution is generally taken over a period of from 10 minutes to 90 minutes, for example from 15 minutes to 1 hour, for example from 20 minutes to 45 minutes, typically 30 minutes.
  • t(d1) is for example 10 to 90 minutes, for example 15 minutes to 1 hour, for example 20 to 45 minutes, typically 30 minutes.
  • t(d2) is for example 10 to 90 minutes, for example 15 minutes to 1 hour, for example 20 to 45 minutes, typically 30 minutes.
  • Each drink of additional clear fluid is generally taken over a period of from 10 minutes to 90 minutes, for example from 15 minutes to 1 hour, for example from 20 minutes to 45 minutes, typically 30 minutes.
  • t(cf1) is for example 10 to 90 minutes, for example 15 minutes to 1 hour, for example 20 to 45 minutes, typically 30 minutes.
  • t(cf2) is for example 10 to 90 minutes, for example 15 minutes to 1 hour, for example 20 to 45 minutes, typically 30 minutes.
  • a subject may take some of the additional clear fluid before completing the ingestion of the cleansing solution (for example the two solutions might be interspersed).
  • t(d1) and t(cf1) may not be distinct.
  • t(d1)+t(cf1) is thus for example 20 minutes to 3 hours, for example 30 minutes to 2 hours, for example 40 to 90 minutes, typically 1 hour.
  • the surgical, therapeutic or diagnostic procedure is carried out within 36 hours (for example within 24 hours) of the start of the colon cleansing. That is to say that t 2 is generally less than 36 hours, for example less than 24 hours, for example less than 20 hours, for example less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4 or less than 3 hours.
  • t 2 is in the range of from 10 to 36 hours; for example from 12 to 24 hours; for example from 12 to 18 hours; for example from 12 to 16 hours.
  • t 2 is in the range of from 3 to 14 hours; for example from 3 to 12 hours, for example from 4 to 10 hours, for example from 4 to 8 hours.
  • the second dose of cleansing solution is generally taken after an interval after the completion of the first additional clear fluid.
  • the length of the interval t(dose interval) may be expressed as:
  • t (dose interval) t 1 ⁇ ( t ( d 1)+ t ( cf 1)).
  • t(dose interval) is in the range of from 0 minutes to 8 hours, for example from 10 minutes to 4 hours, for example from 30 minutes to 4 hours, for example from 30 minutes to two hours, for example one hour or two hours. That is to say that both doses are taken on the same day.
  • t(dose interval) is in the range of from 8 to 20 hours, for example 10 to 16 hours, for example 10 to 14 hours, for example 12 hours.
  • the t(dose interval) may, for example, be selected from 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 hours.
  • the surgical, therapeutic or diagnostic procedure is generally carried out after an interval after the completion of the second additional clear fluid.
  • the length of the interval t(procedure interval) may be expressed as:
  • t (procedure interval) t 2 ⁇ ( t 1 +t ( d 2)+ t ( cf 2)).
  • t(procedure interval) should be long enough for sufficient fluid to have passed through the colon to cleanse it satisfactorily for a colonoscopy examination or other diagnostic procedure, or a therapeutic or surgical procedure to be carried out. For example, it should be long enough for colonic effluent to be clear.
  • t(procedure interval) is from 30 minutes to 10 hours, for example from 1 to 8 hours, for example from 1 to 6 hours.
  • t(procedure interval) is from 8 to 20 hours, for example from 9 to 18 hours, for example from 10 to 16 hours.
  • the t(procedure interval) may, for example, be selected from 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 hours.
  • the invention thus provides a method of cleaning the colon of a subject before a surgical, therapeutic or diagnostic procedure, in which the subject takes two doses of colon cleansing solution whereby the first colon cleansing solution is taken over a time period t(d1) followed by optional additional clear fluid over a time period t(cf1), and then following a time interval t(dose interval), the second colon cleansing solution is taken over a time period t(d2) followed by optional additional clear fluid over a time period t(cf2), whereby the subject undergoes the surgical, therapeutic or diagnostic procedure at a time t 2 after the beginning of the colon cleansing method, and whereby the time interval after the completion of the second additional clear fluid and the start of the surgical, therapeutic or diagnostic procedure is t(procedure interval).
  • the invention provides a method in which:
  • t 2 is in the range of from 10 to 36 hours (for example from 12 to 24 hours, for example from 12 to 16 hours); t(dose interval) is in the range of from 0 minutes to 8 hours (for example from 30 minutes to 4 hours, for example one hour or two hours); and t(procedure interval) is from 8 to 20 hours (for example from 10 to 16 hours).
  • t 2 is in the range of from 10 to 36 hours (for example from 12 to 24 hours, for example from 12 to 16 hours); t(dose interval) is in the range of 8 to 20 hours (for example 10 to 14 hours); and t(procedure interval) is from 30 minutes to 10 hours (for example from 1 to 6 hours).
  • C) t 2 is in the range of from 3 to 14 hours (for example from 4 to 10 hours); t(dose interval) is in the range of from 0 minutes to 8 hours (for example from 30 minutes to 4 hours, for example one hour or two hours); and t(procedure interval) is from 30 minutes to 10 hours (for example from 1 to 6 hours).
  • t(d1) is 15 minutes to 1 hour (for example 30 minutes)
  • t(cf1) is 15 minutes to 1 hour (for example 30 minutes)
  • t(d2) is 15 minutes to 1 hour (for example 30 minutes)
  • t(cf2) is 15 minutes to 1 hour (for example 30 minutes).
  • the second colon cleansing solution is a solution of the invention described above in section 2, or as described below in section 4.
  • the first colon cleansing solution may be the same as the second solution, or it may be different, as set out herein.
  • the subject may additionally take a stimulant laxative (also known as a prokinetic agent).
  • a stimulant laxative can assist in bringing about good cleansing.
  • stimulant laxatives include contact laxatives, for example bisacodyl, castor oil, senna or bisoxatin.
  • stimulant laxatives also include additional osmotic agents for example magnesium salts, for example magnesium citrate. If a stimulant laxative is included in the regimen, the length of the time interval can be shortened. For example, it may be 10 minutes to 15 hours, for example 1 to 15 hours, for example 1 to 12 hours, for example 2 to 10 hours.
  • the subject waits until the bowel movement has occurred before taking the second dose.
  • the solution of the invention may be taken for one or for both of the doses.
  • the solution of the invention is taken as the second dose.
  • the subject may ingest 300 ml to 1000 ml of the solution of the invention as the second dose, for example 300 ml to 900 ml, for example 300 ml to 800 ml, for example 400 ml to 700 ml, for example 400 to 600 ml, for example 450 to 550 ml, for example 500 ml.
  • 300 ml to 1000 ml of the solution of the invention for example 300 ml to 900 ml, for example 300 ml to 800 ml, for example 400 ml to 700 ml, for example 400 to 600 ml, for example 450 to 550 ml, for example 500 ml.
  • 16 or 17 US fluid ounces may be ingested.
  • the first dose of a split dose treatment may be a solution of different constitution from the second dose.
  • a subject takes a dose of an initial cleansing solution, optionally followed by some additional clear fluid. After an interval, the subject then takes a dose of the solution of the invention, optionally followed by some additional clear fluid.
  • the volume of additional clear fluid that a subject ingests after the first or second dose may be in a range with a lower limit of 100 ml, 200 ml, 300 ml, 400 ml or 500 ml.
  • the lower limit is 300 ml, 400 ml or 500 ml.
  • the volume may be in a range with an upper limit of 1200 ml, 1100 ml, 1000 ml, 900 ml or 800 ml.
  • the volume may be in the range 100 ml to 1200 ml, for example 200 ml to 1100 ml, for example 300 ml to 1000 ml, for example 500 ml to 900 ml, for example 1000 ml, for example 875 ml, for example 500 ml to 800 ml.
  • the volume may be in the range 300 ml to 900 ml, for example 400 ml to 800 ml, for example 500 ml to 800 ml.
  • the additional clear fluid may be ingested in a volume of at least 500 ml. For example it may be at least 16 or 17 US fluid ounces.
  • the instructions provided to the subject may suggest that the additional clear fluid is ingested over a period of approximately one hour, for example in 150 to 200 ml fractions every 15 to 20 minutes.
  • the additional clear fluid may be taken after taking a dose of the solution.
  • the additional clear fluid may be co-administered with the intake of a dose of the solution of the invention; for example, the subject may ingest clear fluid between fractions of the solution of the invention; for example the subject may ingest a cup of the solution of the invention, followed by a cup of additional clear fluid, followed by further cups of the solution of the invention.
  • a clear fluid for taking as the additional clear fluid, or for use as the clear fluid when making up a solution may be any fluid that allows inspection of colonic output.
  • the clear fluid should also not impede inspection of the colon during the colonoscopy.
  • the clear fluid is a water-based beverage, including, for example, water, lemonade, cola drinks, cordial drinks, clear fruit juices and even clear alcohol-containing beverages, for example beer. It is desirable that the clear fluid does not contain substantial amounts of or essentially any dietary fibre, as such fibre interferes with the cleansing of the colon according to the present invention. Accordingly, fruit juices, for example orange juice and kiwi juice, and fruit “squashes” should be strained before use.
  • Clear fruit cordials for example lime cordial or tea (for example green tea), are generally suitable.
  • “diet” drinks containing no or low sugar are especially suitable, for example liquid drinks for diabetics, diet Coke®, diet lemonade, dietary carbonated drinks or dietary cordials.
  • the most preferred clear fluid is water.
  • subjects are advised not to eat heavy meals before starting the colon cleansing treatment.
  • a subject may be advised to fast for 12 hours (for example 10 hours, for example 8 hours, for example 6 hours) before starting the colon cleansing treatment.
  • a subject may, for example, be advised to follow a “white diet” for a day before, or the day of the start of the colon cleansing procedure.
  • a “white diet” a subject is instructed to restrict food intake to white and cream-coloured foods.
  • Foods that are allowed include chicken breast (without skin), fish fillets (without skin), eggs, cheeses, rice crackers, white bread, plain pasta, white rice, rice noodle, peeled potato, ice cream, butter, custard, mayonnaise, milk and white chocolate.
  • White foods that are not allowed include coconut, onion, cauliflower, pears, parsnip, semolina, banana and popcorn.
  • a subject may be advised to consume only a light meal, for example plain yoghurt, during that period.
  • the method of the invention may be used to cleanse the colon prior to carrying out a diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen in a subject.
  • the subject is most preferably a human.
  • the diagnostic or surgical procedure may, for example, be colonoscopy (such as cap-assisted colonoscopy and/or narrow-band colonoscopy), barium enema examination, sigmoidoscopy (for example flexible sigmoidoscopy) or colon surgery.
  • the method of the invention may be a method of cleansing the colon prior to a surgical or diagnostic procedure comprising administering the first solution and then after a time interval administering the second solution prior to said procedure.
  • solutions, compositions and kits described herein also find use in the treatment of constipation and fecal impaction. They also find use in the treatment of severe bacterial infections of the bowel.
  • the invention thus provides solutions, compositions and kits as described herein for use in the treatment of constipation or fecal impaction, or in the treatment of severe bacterial infections of the bowel.
  • the invention also provides methods of treating constipation or fecal impaction, or in the treating severe bacterial infections of the bowel comprising administration of solutions as described herein.
  • the solutions of the invention find use in cleansing the colon.
  • the invention provides, in a further aspect, a solution in water of:
  • the solution for use in cleansing the colon of a mammal preferably comprises ascorbate anion in a concentration of: 300-700 mmol per litre, for example 350-650 mmol per litre, for example 450-600 mmol per litre.
  • the ascorbate anion is provided by a mixture of ascorbic acid and one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in section 3a).
  • PEG poly(ethylene glycol)
  • PEG poly(ethylene glycol)
  • Preferred forms of the PEG and preferred amounts thereof are as set out above in section 3a).
  • the solution for use in cleansing the colon of a mammal may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the solution for use in cleansing the colon of a mammal additionally comprises elements c),
  • Preferred electrolytes and preferred amounts thereof are as set out above in section 3a).
  • Preferred alkali metal or alkaline earth metal sulphates and preferred amounts thereof are as set out above in section 3a).
  • flavouring agents and preferred amounts thereof are as set out above in section 3a).
  • Preferred sweeteners and preferred amounts thereof are as set out above in section 3a).
  • the solution in water comprises:
  • the invention provides a solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be as described above and/or be present in the amounts described above in section 3a).
  • Each of e) and f) may be as described above and/or be in the amounts described above section 3).
  • the invention provides a solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • Each of c) and d) may be as described above and/or be present in the amounts described above in section 3a).
  • Each of e) and f) may be as described above and/or be in the amounts described above section 3a).
  • the invention provides a solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 1.20 g per litre orange flavour and 3.86 g per litre aspartame.
  • the flavouring and sweetener may be 3.20 g per litre citrus flavour and 1.75 g per litre aspartame.
  • the flavouring and sweetener may be 4.20 g per litre orange grapefruit flavour and 1.75 g per litre aspartame.
  • a colon cleansing treatment typically involves a subject taking a single dose or a split dose of cleansing solution.
  • the volume of solution that a subject takes in a single dose treatment is described hereinabove.
  • the subject may take some additional clear fluid after taking the solution as described hereinabove.
  • the volume of solution that a subject takes in a split dose treatment is described hereinabove.
  • the subject may take some additional clear fluid after each or either dose the solution as described hereinabove.
  • the invention further provides a composition (for example a dry composition, for example a powder) for the preparation of a solution of the invention.
  • a composition can be in a quantity for the preparation of a dose of the solution, for example a 500 ml dose (for example a 16 or 17 US fluid ounce dose).
  • the invention provides a composition for admixture with water, wherein the composition is optionally presented in two or more parts and comprises:
  • the components may be in dry powder, granular or other dry form. They may alternatively be in the form of concentrates or slurries. Components may be in the same or different physical forms.
  • the composition is a dry composition, for example a dry powder composition.
  • one or both of components a) and b) are dry powders. In a dry powder, it is possible for one or more components to be a salt hydrate.
  • the ascorbate anion is provided by a mixture of ascorbic acid and one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in relation to solutions of the invention.
  • composition of the invention preferably comprises ascorbate anion in an amount of 150 to 350 mmol, for example 175-325 mmol, for example 225-300 mmol.
  • the 150 to 400 mmol ascorbate anion can be provided by 3.3 to 12.8 g ascorbic acid and 24.3 to 69 g sodium ascorbate, for example 5.0 to 10 g ascorbic acid and 40 to 60 g sodium ascorbate; for example 6.0 to 10 g ascorbic acid and 40 to 60 g sodium ascorbate; for example 7.0 to 8.0 g ascorbic acid and 44 to 52 g sodium ascorbate; for example 7.0 to 8.0 g ascorbic acid and 46 to 50 g sodium ascorbate.
  • Potassium ascorbate has a molecular weight of 214 g/mol. Accordingly, the 150 to 400 mmol ascorbate anion can be provided by 3.3 to 12.8 g ascorbic acid and 26 to 75 g potassium ascorbate, for example 5.0 to 10 g ascorbic acid and 45 to 65 g potassium ascorbate; for example 7.0 to 8.0 g ascorbic acid and 47 to 56 g sodium ascorbate.
  • Magnesium ascorbate has a molecular weight of 374.5 g/mol and each mole of magnesium ascorbate provides two moles of ascorbate. Accordingly, the 150 to 400 mmol ascorbate anion can be provided by 3.3 to 12.8 g ascorbic acid and 23 to 65 g magnesium ascorbate, for example 5.0 to 10 g ascorbic acid and 38 to 57 g magnesium ascorbate; for example 7.0 to 8.0 g ascorbic acid and 42 to 49 g magnesium ascorbate.
  • ascorbic acid is typically made up of protonated free ascorbic acid.
  • concentrations of “ascorbate anion” herein the number of moles of “ascorbate anion” is taken as the total concentration of all ascorbate anion present, including the proportion that is protonated.
  • the weight of the ascorbate component may be 20 to 85 g, for example 25 to 75 g, for example 20 to 60 g, for example 50 to 60 g.
  • the ascorbate component comprises (or consists essentially of) sodium ascorbate and ascorbic acid.
  • they may be present in a total amount and in a weight ratio as mentioned immediately above.
  • the composition comprises 5 to 100 g of PEG.
  • the composition comprises 10 to 80 g of PEG, more preferably 20 to 60 g, for example 30 to 50 g, for example 37.5 to 42.5 g, for example 40 g of PEG.
  • composition may additionally comprise one or more of:
  • flavouring agents e) one or more flavouring agents
  • the composition may comprise sodium chloride in an amount of 0.5 to 5 g, for example 1.5 to 4 g, for example 2.0 to 3.5 g, for example 2.8 g or 3.2 g.
  • the composition may comprise potassium chloride in an amount of 0.5 to 5 g, for example 0.5 to 3.5 g, for example 0.75 to 2.5 g, for example 0.75 to 1.5 g, for example 1.0 to 1.4 g, for example 1.2 g or 1.3 g.
  • the composition is essentially free from sodium bicarbonate, for example essentially free from any bicarbonate.
  • the composition may comprise a sulphate component in an amount of 1 to 10 g, for example 2.5 to 7.5 g, for example 4 to 7.5 g, for example 5 to 7 g, for example 6 g.
  • the one or more sulphate salts may be provided in any pharmaceutically acceptable form: they may each be anhydrous, or be in a hydrated form.
  • the weights mentioned herein refer to the weight of the sulphate salt excluding any water of hydration.
  • a hydrate form may be present in the dry powder composition, and that composition is still considered “dry” herein.
  • the composition does not comprise a sulphate component; that is to say that the composition is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • flavouring agents are as set out above in section 3a), in relation to solutions of the invention.
  • the amount of flavouring agent may be 0.025 to 2.25 g, for example 0.025 to 1.0 g, for example 0.1 to 0.9 g, for example 0.5 to 0.9 g, for example 1.5 to 2.25 g, for example 0.15 g or 0.6 g, for example 1.6 or 2.1 g.
  • Preferred sweeteners are as set out above in section 3a), in relation to solutions of the invention.
  • the amount of sweetener required depends on the nature and strength of the sweetener being considered.
  • the amount of sweetener may be 0.05 to 2 g, for example 0.25 to 2 g, for example 1.25 to 2 g, for example 1.5 g, for example 1.93 g.
  • Those quantities of aspartame are particularly suitable when used with orange flavouring, for example orange flavouring at 0.1 to 0.9 g, for example 0.5 to 0.9 g, for example 0.15 g, 0.4375 g or 0.6 g.
  • the sweetener may be aspartame at 0.5 to 1.25 g, for example 0.75 to 1.0 g, for example 0.875 g.
  • the invention provides a composition comprising:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be present in the amounts described above.
  • Each of e) and f) may be as described above and/or be in the amounts described above.
  • the invention provides a composition comprising: a)
  • flavouring agents e) one or more flavouring agents
  • the invention provides a composition comprising:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 0.60 g orange flavour and 1.93 g aspartame.
  • the flavouring and sweetener may be 1.60 g citrus flavour and 0.875 g aspartame.
  • the flavouring and sweetener may be 2.10 g orange grapefruit flavour and 0.875 g aspartame.
  • the composition consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the composition may, for example, not contain any sulphate.
  • One or more of components a) to f) may be presented in solid form, or in semi-solid form (for example in gel form).
  • the one or more components of c), d) (when present), e) and f) are present in the composition for making up a solution.
  • some or all of components c), d) (when present), e) and f) may be provided separately from the composition for making up the solution, for example in a tablet or capsule.
  • the flavouring and sweeteners need not be the same in the tablet or capsule as in the composition for admixture with water.
  • the ascorbate and the PEG components separately from each other.
  • the composition can be provided to the subject with a plurality of flavouring agents (each optionally with one or more sweeteners), each separately packaged.
  • the subject can then select a preferred flavouring (or flavouring and sweetener combination) according to his or her taste.
  • the subject also has the choice of not using any flavouring or sweetener at all.
  • the invention further provides a solution (for example a 500 ml dose) prepared by admixing a composition of the invention with the requisite volume of water.
  • compositions described herein are of a nature and quality suitable for mammalian (especially human) consumption.
  • they are of pharmaceutical grade.
  • the pharmaceutically acceptable compositions described herein may be provided in packaged form with instructions for use.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • the components may be in dry powder, granular or other dry form. They may alternatively be in the form of concentrates or slurries. Components may be in the same or different physical forms.
  • the composition is a dry composition, for example a dry powder composition.
  • one or both of components a) and b) are dry powders.
  • the ascorbate anion is provided by a mixture of ascorbic acid and one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in section 3a) in relation to solutions of the invention.
  • the composition of the invention preferably comprises ascorbate anion in a weight ratio to PEG of 0.82 to 3.0:1. More preferably, the weight ratio is 0.9 to 2.0:1, for example 1.0 to 1.5:1, for example 1.2 to 1.3:1.
  • the ascorbate anion is provided by ascorbic acid and a salt of ascorbic acid in a ratio of 1:4.5 to 1:7.0.
  • the molar ratio of the ascorbic acid and the one or more salts of ascorbic acid is from 1:4.75 to 1:6.75; more preferably from 1:5.0 to 1:6.0; for example from 1:5.40 to 1:5.80; for example 15:85.
  • the salt of ascorbic acid can be sodium ascorbate.
  • a mixture of ascorbic acid and sodium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 has ascorbic acid and sodium ascorbate present in a weight ratio of 1:5.063 to 1:7.875.
  • a more preferred ratio is 1:5.344 to 1:7.594; more preferably from 1:5.625 to 1:6.75; for example from 1:6.075 to 1:6.525, for example 1:6.38.
  • the weight ratio of ascorbate anion to PEG is 0.82 to 3.0:1, and in which the ascorbate anion is provided by ascorbic acid and a sodium ascorbate in a molar ratio of 1:4.5 to 1:7.0, the weight ratio of ascorbic acid:sodium ascorbate:PEG is 0.1031 to 0.5486:0.7591-2.970:1.
  • the weight ratio can be 0.12 to 0.30:0.9 to 1.9:1; more preferably 0.15 to 0.25:1.0 to 1.5:1; for example 0.185 to 0.190:1.15 to 1.25:1; for example 0.1885:1.203:1.
  • composition may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the composition may comprise sodium chloride in a weight ratio to PEG of 0.005 to 0.5:1, for example 0.01 to 0.3:1, for example 0.03 to 0.2:1, for example 0.04 to 0.15:1, for example 0.05 to 0.1:1, for example 0.06 to 0.09:1.
  • the composition may comprise potassium chloride in a weight ratio to PEG of 0.005 to 0.30:1, for example 0.01 to 0.20:1, for example 0.01 to 0.10:1, for example 0.02 to 0.04:1.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • composition is preferably essentially free from sodium bicarbonate.
  • it is essentially free from any bicarbonate.
  • the composition may comprise a sulphate component (for example sodium sulphate) in a weight ratio to PEG of 0.01 to 0.50:1,
  • the composition may comprise a sulphate component (for example sodium sulphate) in a weight ratio to PEG of 0.02 to 0.25:1, for example 0.03 to 0.22:1, for example 0.05 to 0.20:1, for example 0.10 to 0.20:1.
  • the composition does not comprise a sulphate component; that is to say that the composition is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • flavouring agents are as set out above in section 3a) in relation to solutions of the invention.
  • the composition may comprise a flavouring agent in a weight ratio to PEG of 0.0005 to 0.050:1, for example 0.001 to 0.025:1, for example 0.0025 to 0.020:1.
  • compositions may comprise a sweetener in a weight ratio to PEG of 0.0005 to 0.1:1, for example 0.001 to 0.075:1, for example 0.002 to 0.050:1.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be present in the weight ratios to PEG described above.
  • Each of e) and f) may be as described above and/or be in the weight ratios to PEG described above.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • flavouring agents 0.001 to 0.075 parts
  • one or more sweeteners 0.002 to 0.050 parts.
  • composition may comprise the following components in the following weight ratios:
  • flavouring agents 0.001 to 0.075 parts
  • one or more sweeteners 0.002 to 0.050 parts.
  • flavouring and sweetener may be 0.015 parts orange flavour and 0.048 parts aspartame.
  • flavouring and sweetener may be 0.040 parts citrus flavour and 0.022 parts aspartame.
  • flavouring and sweetener may be 0.053 parts orange grapefruit flavour and 0.022 parts aspartame.
  • the composition consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the composition may, for example, not contain any sulphate.
  • compositions of the invention are dry compositions, for example dry powder compositions.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • the salt of ascorbic acid can be sodium ascorbate.
  • a mixture of ascorbic acid and sodium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 has ascorbic acid and sodium ascorbate present in a weight ratio of 1:5.063 to 1:7.875.
  • a more preferred ratio is 1:5.344 to 1:7.594; more preferably from 1:5.625 to 1:6.75; for example from 1:6.075 to 1:6.525, for example 1:6.38.
  • the invention further provides a method of preparing a solution of the invention comprising combining the components of the solution with water.
  • the method comprises the step of combining the components with water and admixing.
  • Some or all of the components may be in physical association with each other before the water is added.
  • the components of the composition are provided in more than one part; that is to say that they are packaged separately. All of the components may be combined with each other before combining with water. For example, if flavouring agent and sweetener are packaged separately from other components, they may be combined with the other components before combining with water.
  • One or some of the components may be combined with water and admixed in a first step and then some or all of the remaining components may be added in a second step.
  • the components may be in dry form, for example in powder form.
  • the invention provides a composition (for example a dry composition, for example a powder) for the preparation of a solution of the invention.
  • the invention further provides a method of preparing a composition of the invention comprising combining the components of the composition.
  • the method may be a method of preparing a composition of the invention in powder form.
  • the components for the preparation of a solution of the invention may be presented in two or more parts.
  • the invention thus further provides a method of preparing a composition of the invention comprising combining some, but not all of the components of the composition.
  • the invention thus provides a method comprising blending a mixture of:
  • the salt of ascorbic acid can be sodium ascorbate.
  • a mixture of ascorbic acid and sodium ascorbate in a molar ratio of from 1:4.5 to 1:7.0 has ascorbic acid and sodium ascorbate present in a weight ratio of 1:5.063 to 1:7.875.
  • a more preferred ratio is 1:5.344 to 1:7.594; more preferably from 1:5.625 to 1:6.75; for example from 1:6.075 to 1:6.525, for example 1:6.38.
  • the method may comprise blending a mixture of:
  • Preferred salts of ascorbic acid are as set out above in section 3a).
  • Preferred ratios of components (i) and (ii) are as set out above in section 3a).
  • the method may further comprise blending a mixture of:
  • the components may be weighed out and added together before blending, or the components may be added into a blend mixture in any desired order.
  • Blending of the compositions in bulk may, for example, be carried out on a 100 Kg, 500 Kg or 1000 Kg scale. After blending, the composition is divided into smaller portions for packaging into dosage amounts.
  • the invention thus provides a method comprising the step of dividing bulk composition as set out in section 3e) above into smaller portions.
  • the invention also provides a method comprising the step of filling containers with individual dosage amounts of bulk composition as set out in section 3e).
  • the invention thus provides a method comprising the step of filling a container with a composition as set out in section 3d).
  • the composition as set out in section 3d) may be presented in two or more parts.
  • the method may thus comprise the step of filling a container with some but not all of the components of a composition as set out in section 3d).
  • the invention also provides a colon cleansing solution that does not contain any ascorbic acid.
  • the invention thus provides, in a second aspect, a colon cleansing solution comprising:
  • the solution being essentially free from ascorbic acid.
  • the solution of the invention has advantageous properties.
  • the solution of the invention has a surprisingly palatable taste and it is highly effective as a colon cleansing solution with a good tolerability profile.
  • the solutions of the invention are aqueous solutions.
  • Suitable salts of ascorbic acid include alkali metal salts and alkaline earth metal salts.
  • a salt may be selected from sodium, potassium, magnesium and calcium salts.
  • preferred salts of ascorbic acid include sodium ascorbate, potassium ascorbate, magnesium ascorbate and calcium ascorbate.
  • Particularly preferred salts of ascorbic acid are magnesium ascorbate and sodium ascorbate, for example sodium ascorbate.
  • the solution comprises sodium ascorbate and no further ascorbate.
  • the solution of the invention preferably comprises ascorbate anion in a concentration of: 370-430 mmol per litre, for example 380-420 mmol per litre, for example 400-410 mmol per litre.
  • a solution of the invention may comprise 72 to 88 g/litre of ascorbate salt.
  • a solution of the invention comprises 75 to 85 g/litre, for example 78 to 82 g/litre, for example 80 g/litre.
  • Sodium ascorbate has a molecular weight of 198 g/mol. Accordingly, a solution of the invention may comprise sodium ascorbate at 71.3-87.1 g per litre, for example 73.3-85.1 g per litre for example 75.2-83.2 g per litre, for example 79.2-80.2 g per litre.
  • Potassium ascorbate has a molecular weight of 214 g/mol. Accordingly, a solution of the invention may comprise potassium ascorbate at 77.0-94.2 g per litre, 79.2-92.0 g per litre, for example 81.3-89.9 g per litre, for example 85.6-86.7 g per litre.
  • Magnesium ascorbate has a molecular weight of 374.5 g/mol and each mole of magnesium ascorbate provides two moles of ascorbate. Accordingly, a solution of the invention may comprise magnesium ascorbate at 67.4-82.4 g per litre, for example 69.3-80.5 g per litre, for example 71.2-78.6 g per litre, for example 74.9-75.8 g per litre.
  • ascorbate anion may be protonated and thus exist as free ascorbic acid in solution. At the pH of solutions that would typically be administered, only a minor proportion of ascorbate is protonated. In calculations of concentrations of “ascorbate anion” herein, the concentration of “ascorbate anion” is taken as the total concentration of all ascorbate anion present, including the proportion that is protonated.
  • the cleansing solution comprises polyethylene glycol.
  • the polyethylene glycol (PEG) may be as described above in section 3a).
  • the cleansing solution comprises 10 to 200 g per litre of PEG.
  • the solution comprises 20 to 160 g per litre of PEG, more preferably 40 to 120 g per litre, for example 60 to 100 g per litre, for example 75 to 85 g per litre, for example 80 g per litre.
  • the cleansing solution may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the cleansing solution may comprise one or more electrolytes. Electrolytes include salts of sodium, potassium, calcium and magnesium, particularly sodium and potassium; and salts of chloride, iodide, bicarbonate and carbonate, particularly chloride. Preferred electrolytes are sodium chloride and potassium chloride. In an embodiment, the solution is essentially free from sodium bicarbonate, for example essentially free from any bicarbonate.
  • the solution may comprise sodium chloride at a concentration of 1 to 10 g per litre.
  • sodium chloride may be present at a concentration of 3 to 8 g per litre, for example 4 to 7 g per litre; for example 4.5 to 5.5 g per litre; for example 5.0 g per litre or 5.6 g per litre.
  • the solution may comprise potassium chloride at a concentration of 1 to 10 g per litre.
  • potassium chloride may be present at a concentration of 1 to 7 g per litre, for example 1.5 to 5 g per litre, for example 1.5 to 3 g per litre, for example 1.7 to 2.8 g per litre; for example 1.8 g per litre or 2.6 g per litre.
  • the solution comprises sodium chloride and potassium chloride. They can be present in the amounts mentioned immediately above.
  • sodium chloride may be present at a concentration of 4 to 7 g per litre and potassium chloride may be present at a concentration of 1.5 to 3 g per litre.
  • the cleansing solution may comprise one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof (herein referred to as a “sulphate component”).
  • the sulphate component and the quantity thereof may be as described above in section 3a).
  • the solution does not comprise a sulphate component; that is to say that the solution is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • the quantities of the individual components recited do not include any solutes that may be present in the water used to prepare the solutions, for example, in hard water areas there may be significant amounts of Ca 2+ and Mg 2+ carbonates, bicarbonates or sulphates present in tap water.
  • the cleansing solution preferably includes a flavouring agent.
  • the flavouring may be as described above in section 3a). Lemon/lime flavour and orange flavour are particularly preferred.
  • the amount of flavouring required depends on the nature and strength of the flavouring in question. Typically, it is 0.05 to 4.5 g per litre, for example 0.05 to 2.0 g per litre, for example 0.5 to 1.8 g per litre, for example 2.5 to 4.5 g per litre, for example 0.6 g per litre or 1.6 g per litre, for example 3.2 or 4.3 g per litre.
  • the cleansing solution preferably includes a sweetener.
  • the sweetener may be as described above in section 3a).
  • compositions of the invention can be essentially free from added sweeteners, for example to minimize the number of different components in the compositions.
  • a souring agent for example citric acid
  • a souring agent is a component that imparts a sourness to a composition.
  • Other souring agents include malic acid, acetic acid, tartaric acid, gluconodeltalactone, phosphoric acid, succinic acid, phytic acid, lactic acid or salts thereof.
  • the souring agent (for example citric acid) may be provided in an encapsulated form.
  • the encapsulation provides a coating that isolates the souring agent from other components and from air and moisture prior to its use.
  • the encapsulation may be with a water-soluble coating.
  • the amount of sweetener required depends on the nature and strength of the sweetener being considered. Typically, it is 0.10 to 4 g per litre.
  • the sweetener may be aspartame at 0.5 to 4 g per litre, for example 2.5 to 4.0 g per litre, for example 2.0 g per litre, for example 2.2 g per litre or 3.25 g per litre.
  • aspartame are particularly suitable when used with orange flavouring, for example orange flavouring at 0.2 to 1.8 g per litre, for example 0.5 to 1.8 g per litre, for example 0.6 g per litre or 1.6 g per litre or 3.25 g per litre.
  • the invention thus provides a colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • the solution being essentially free from ascorbic acid.
  • the invention provides a colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • the solution being essentially free from ascorbic acid.
  • Each of c) and d) may be present in the concentrations described above.
  • Each of e) and f) may be as described above and/or be in the concentrations described above.
  • the invention provides a colon cleansing solution comprising:
  • flavouring agents e) one or more flavouring agents
  • the solution being essentially free from ascorbic acid.
  • the one or more components of c), d) (when present), e) and f) are present in the solution.
  • some or all of components c), d) (when present), e) and f) may be provided separately from the solution, for example in a tablet or capsule.
  • the solution may comprise a) the ascorbate component and b) PEG, and optional flavouring and sweetener (e) and f)), and a tablet or capsule may comprise c) the one or more electrolytes and/or d) the one or more alkali metal or alkaline earth metal sulphates, again with optional flavouring and sweetener (e) and f)).
  • the flavouring and sweeteners need not be the same in the tablet or capsule as in the solution.
  • the invention provides a colon cleansing solution comprising:
  • flavouring agents e) one or more flavouring agents
  • the solution consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the solution may, for example, not contain any sulphate.
  • the invention provides a solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the invention provides a colon cleansing solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 1.60 g per litre orange flavour and 2.20 g per litre aspartame.
  • the flavouring and sweetener may be 3.20 g per litre lemon/lime flavour and 3.25 g per litre aspartame.
  • the flavouring and sweetener may be 4.30 g per litre orange grapefruit flavour and 3.25 g per litre aspartame.
  • the colon cleansing solution is hyper-osmotic. That is to say that it has a higher osmotic strength than blood in the human body. It may, for example have a measured osmolality in the range 500 to 2000 mOsmol/kg.
  • the osmolality may be in the range 700 to 1800 mOsmol/kg.
  • the solutes in 500 ml of the solution may have a measured V(350) value of from 1000 to 2000 ml, for example from 1300 to 1700 ml, for example from 1400 to 1600 ml, and be in a volume of 400 to 600 ml, for example 500 ml.
  • the invention provides a colon cleansing solution comprising:
  • the solution being essentially free from ascorbic acid, and 500 ml of the solution having a V(350) osmolality value of from 1000 to 2000 ml.
  • 500 ml of the solution may have a V(350) osmolality value of from 1200 to 1800 ml, for example from 1400 to 1600 ml.
  • solutions of the invention may include additional optional components as set out above in section 3b).
  • the solution for use in cleansing the colon of a mammal preferably comprises ascorbate anion in a concentration of: 370-430 mmol per litre, for example 380-420 mmol per litre, for example 400-410 mmol per litre.
  • the ascorbate anion is provided by one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in section 5a).
  • PEG poly(ethylene glycol)
  • PEG poly(ethylene glycol)
  • Preferred forms of the PEG and preferred amounts thereof are as set out above in section 5a).
  • the solution for use in cleansing the colon of a mammal may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the solution for use in cleansing the colon of a mammal additionally comprises elements c),
  • Preferred electrolytes and preferred amounts thereof are as set out above in section 5a).
  • Preferred alkali metal or alkaline earth metal sulphates and preferred amounts thereof are as set out above in section 5a).
  • flavouring agents and preferred amounts thereof are as set out above in section 5a).
  • Preferred sweeteners and preferred amounts thereof are as set out above in section 5a).
  • the solution in water comprises:
  • the solution being essentially free from ascorbic acid.
  • the invention provides a solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be as described above and/or be present in the amounts described above in relation to solutions of the invention.
  • Each of e) and f) may be as described above and/or be in the amounts described above in section 5a).
  • the invention provides a solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the invention provides a solution consisting essentially of:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 1.60 g per litre orange flavour and 2.20 g per litre aspartame.
  • the flavouring and sweetener may be 3.20 g per litre lemon/lime flavour and 3.25 g per litre aspartame.
  • the flavouring and sweetener may be 4.30 g per litre orange grapefruit flavour and 3.25 g per litre aspartame.
  • a colon cleansing treatment typically involves a subject taking a single dose or a split dose of cleansing solution.
  • the volume of solution that a subject takes in a single dose treatment is described hereinabove in section 3c).
  • the subject may take some additional clear fluid after taking the solution as described hereinabove.
  • the volume of solution that a subject takes in a split dose treatment is described hereinabove in section 3c).
  • the subject may take some additional clear fluid after each or either dose the solution as described hereinabove.
  • the invention further provides a composition (for example a dry composition, for example a powder) for the preparation of a solution of the invention.
  • a composition can be provided in a quantity for the preparation of a dose of the solution, for example a 500 ml dose.
  • the invention provides a composition for admixture with water, wherein the composition is optionally presented in two or more parts and comprises:
  • the solution being essentially free from ascorbic acid.
  • the components may be in dry powder, granular or other dry form. They may alternatively be in the form of concentrates or slurries. Components may be in the same or different physical forms.
  • the composition is a dry composition, for example a dry powder composition.
  • a dry powder composition for example, one or both of components a) and b) are dry powders.
  • the ascorbate anion may be provided by one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in relation to solutions of the invention.
  • composition of the invention preferably comprises ascorbate anion in an amount of: 185 to 215 mmol, for example 190 to 210 mmol, for example 200-205 mmol.
  • Sodium ascorbate has a molecular weight of 198 g/mol. Accordingly, the 180 to 220 mmol ascorbate anion can be provided by 35.6 to 43.6 g sodium ascorbate.
  • the sodium ascorbate may be present at a level of 36.6 to 42.6 g, for example 37.6 to 41.6 g, for example 39.6 to 40.6 g.
  • Potassium ascorbate has a molecular weight of 214 g/mol. Accordingly, the 180 to 220 mmol ascorbate anion can be provided by 38.5 to 47.1 g potassium ascorbate.
  • the potassium ascorbate may be present at a level of 39.6 to 46.0 g, for example 40.7 to 44.9 g, for example 42.8 to 43.9 g.
  • Magnesium ascorbate has a molecular weight of 374.5 g/mol and each mole of magnesium ascorbate provides two moles of ascorbate. Accordingly, the 180 to 220 mmol ascorbate anion can be provided by 33.7 to 41.2 g magnesium ascorbate.
  • the magnesium ascorbate may be present at a level of 34.6 to 40.3 g, for example 35.6 to 39.3 g, for example 37.5 to 38.4 g.
  • the weight of the ascorbate salt component may be 33 to 47 g, for example 35 to 45 g, for example 37 to 43 g.
  • the ascorbate component consists essentially of sodium ascorbate alone.
  • it may be present in an amount as mentioned immediately above.
  • the composition comprises 5 to 100 g of PEG.
  • the composition comprises 10 to 80 g of PEG, more preferably 20 to 60 g, for example 30 to 50 g, for example 37.5 to 42.5 g, for example 40 g of PEG.
  • composition may additionally comprise one or more of:
  • flavouring agents e) one or more flavouring agents
  • the composition may comprise sodium chloride in an amount of 0.5 to 5 g, for example 1.5 to 4 g, for example 2.0 to 3.5 g, for example 2.5 or 2.8 g.
  • the composition may comprise potassium chloride in an amount of 0.5 to 5 g, for example 0.5 to 3.5 g, for example 0.75 to 2.5 g, for example 0.75 to 1.5 g, for example 0.85 to 1.4 g, for example 0.9 or 1.3 g.
  • the composition is essentially free from sodium bicarbonate, for example essentially free from any bicarbonate.
  • the composition may comprise a sulphate component in an amount of 1 to 10 g, for example 2.5 to 7.5 g, for example 4 to 7.5 g, for example 5 to 7 g, for example 6 g.
  • the one or more sulphate salts may be provided in any pharmaceutically acceptable form: they may each be anhydrous, or be in a hydrated form.
  • the weights mentioned herein refer to the weight of the sulphate salt excluding any water of hydration.
  • a hydrate form may be present in the dry powder composition, and that composition is still considered “dry” herein.
  • the composition does not comprise a sulphate component; that is to say that the solution is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • flavouring agents are as set out above in section 5a) in relation to solutions of the invention.
  • the amount of flavouring agent may be 0.025 to 2.25 g, for example 0.025 to 1.0 g, for example 0.25 to 0.9 g, for example 1.25 to 2.25 g, for example 0.3 g or 0.8 g, for example 1.6 or 2.15 g.
  • the amount of sweetener may be 0.05 to 2 g.
  • the sweetener may be aspartame at 0.25 to 2 g, for example at 1.25 to 2.0 g, for example 1.0, 1.1 g or 1.625 g.
  • Those quantities of aspartame are particularly suitable when used with orange flavouring, for example orange flavouring at 0.1 to 0.9 g, for example 0.25 to 0.9 g, for example 0.3, 0.8 g or 1.625 g.
  • the invention provides a composition comprising:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be present in the amounts described above.
  • Each of e) and f) may be as described above and/or be in the amounts described above.
  • composition comprising:
  • flavouring agents e) one or more flavouring agents
  • the invention provides a composition comprising:
  • flavouring agents e) one or more flavouring agents
  • the flavouring and sweetener may be 0.80 g orange flavour and 1.10 g aspartame.
  • the flavouring and sweetener may be 1.60 g lemon/lime flavour and 1.625 g aspartame.
  • the flavouring and sweetener may be 2.15 g orange grapefruit flavour and 1.625 g aspartame.
  • the composition consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the composition may, for example, not contain any sulphate.
  • One or more components a) to f) may be presented in solid form, or in semi-solid form (for example in gel form).
  • the one or more components of c), d) e) and f) are present in the composition for making up a solution.
  • some or all of components c), d) e) and f) may be provided separately from the composition for making up the solution, for example in a tablet or capsule.
  • the flavouring and sweeteners need not be the same in the tablet or capsule as in the composition for admixture with water.
  • the ascorbate and the PEG components separately from each other.
  • the composition can be provided to the subject with a plurality of flavouring agents (each optionally with one or more sweeteners), each separately packaged.
  • the subject can then select a preferred flavouring (or flavouring and sweetener combination) according to his or her taste.
  • the subject also has the choice of not using any flavouring or sweetener at all.
  • compositions described herein are of a nature and quality suitable for mammalian (especially human) consumption.
  • they are of pharmaceutical grade.
  • the pharmaceutically acceptable compositions described herein may be provided in packaged form with instructions for use.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • the ascorbate anion being provided by one or more salts of ascorbic acid;
  • composition being essentially free from ascorbic acid.
  • the components may be in dry powder, granular or other dry form. They may alternatively be in the form of concentrates or slurries. Components may be in the same or different physical forms.
  • the composition is a dry composition, for example a dry powder composition.
  • one or both of components a) and b) are dry powders.
  • the ascorbate anion is provided by one or more salts of ascorbic acid.
  • Preferred forms of the ascorbate component are as set out above in section 5a) in relation to solutions of the invention.
  • Preferred salts are sodium, potassium and magnesium ascorbate, especially sodium ascorbate.
  • composition of the invention preferably comprises ascorbate anion in a weight ratio to PEG of 0.80 to 1.0:1. More preferably, the weight ratio is 0.85 to 0.95:1, for example 0.86 to 0.90:1, for example 0.88:1.
  • the preferred ascorbate salt is sodium ascorbate.
  • the composition of the invention preferably comprises sodium ascorbate and PEG in a weight ratio of 0.90 to 1.125:1. More preferably, the weight ratio is 0.956 to 1.069:1, for example 0.968 to 1.013:1, for example 0.99:1, for example 1:1.
  • composition may additionally comprise one or more of:
  • flavouring agents one or more flavouring agents
  • the composition may comprise sodium chloride in a weight ratio to PEG of 0.005 to 0.5:1, for example 0.01 to 0.3:1, for example 0.02 to 0.2:1, for example 0.03 to 0.15:1, for example 0.04 to 0.1:1, for example 0.05 to 0.08:1.
  • the composition may comprise potassium chloride in a weight ratio to PEG of 0.005 to 0.30:1, for example 0.01 to 0.20:1, for example 0.01 to 0.10:1, for example 0.02 to 0.04:1.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • c2) potassium chloride 0.005 to 1.0 parts; the ascorbate anion being provided by one or more salts of ascorbic acid; the composition being essentially free from ascorbic acid.
  • composition is preferably essentially free from sodium bicarbonate.
  • it is essentially free from any bicarbonate.
  • the composition may comprise a sulphate component (for example sodium sulphate) in a weight ratio to PEG of 0.01 to 0.50:1,
  • the composition may comprise a sulphate component (for example sodium sulphate) in a weight ratio to PEG of 0.02 to 0.25:1, for example 0.03 to 0.22:1, for example 0.05 to 0.20:1, for example 0.10 to 0.20:1.
  • the composition does not comprise a sulphate component; that is to say that the composition is essentially free from alkali metal sulphates and alkaline earth metal sulphates; in particular essentially free from sodium sulphate, potassium sulphate and magnesium sulphate.
  • flavouring agents are as set out above in section 5a) in relation to solutions of the invention.
  • the composition may comprise a flavouring agent in a weight ratio to PEG of 0.0005 to 0.05:1, for example 0.001 to 0.050:1, for example 0.003 to 0.030:1.
  • compositions may comprise a sweetener in a weight ratio to PEG of 0.0005 to 0.025:1, for example 0.001 to 0.050:1, for example 0.01 to 0.035:1.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • flavouring agents optionally one or more flavouring agents
  • the ascorbate anion being provided by one or more salts of ascorbic acid; the composition being essentially free from ascorbic acid.
  • Each of c) and d) may be present in the weight ratios to PEG described above.
  • Each of e) and f) may be as described above and/or be in the weight ratios to PEG described above.
  • the invention provides a composition comprising the following components in the following weight ratios:
  • flavouring agents 0.001 to 0.075 parts
  • one or more sweeteners 0.002 to 0.050 parts.
  • composition may comprise the following components in the following weight ratios:
  • flavouring agents 0.001 to 0.075 parts
  • one or more sweeteners 0.002 to 0.050 parts.
  • the flavouring and sweetener may be 0.020 parts orange flavour and 0.0275 parts aspartame.
  • the flavouring and sweetener may be 0.040 parts lemon/lime flavour and 0.041 parts aspartame.
  • the flavouring and sweetener may be 0.054 parts orange flavour and 0.041 parts aspartame.
  • the composition consists essentially of those components; that is to say that it does not contain any further components in significant quantities.
  • the composition may, for example, not contain any sulphate.
  • compositions of the invention are dry compositions, for example dry powder compositions.
  • the invention further provides a method of preparing a solution of the invention comprising combining the components of the solution with water.
  • the method comprises the step of combining the components with water and admixing.
  • Some or all of the components may be in physical association with each other before the water is added.
  • the components of the composition are provided in more than one part; that is to say that they are packaged separately. All of the components may be combined with each other before combining with water. For example, if flavouring agent and sweetener are packaged separately from other components, they may be combined with the other components before combining with water.
  • One or some of the components may be combined with water and admixed in a first step and then or all of the remaining components may be added in a second step.
  • the components may be in dry form, for example in powder form.
  • the invention provides a composition (for example a dry composition, for example a powder) for the preparation of a solution of the invention.
  • the invention further provides a method of preparing a composition of the invention comprising combining the components of the composition.
  • the method may be a method of preparing a composition of the invention in powder form.
  • the method may comprise blending a mixture of:
  • the ascorbate anion being provided by one or more salts of ascorbic acid;
  • composition being essentially free from ascorbic acid
  • Preferred ascorbate salts are as set out above in section 5a). Preferred ratios of components a) and b) as as set out above in section 5a). Preferably the ascorbate anion is in a weight ratio to PEG of 0.80 to 1.0:1. More preferably, the weight ratio is 0.85 to 0.95:1, for example 0.86 to 0.90:1, for example 0.88:1.
  • the preferred ascorbate salt is sodium ascorbate.
  • the sodium ascorbate and PEG are in a weight ratio of 0.90 to 1.125:1. More preferably, the weight ratio is 0.956 to 1.069:1, for example 0.968 to 1.013:1, for example 0.99:1, for example 1:1.
  • the method may further comprise blending a mixture of:
  • the ascorbate anion being provided by one or more salts of ascorbic acid;
  • composition being essentially free from ascorbic acid.
  • Preferred ratio amounts of sodium chloride to PEG and potassium chloride to PEG are as set out above in section 5e).
  • the components may be weighed out and added together before blending, or the components may be added into a blend mixture in any desired order.
  • Blending of the compositions in bulk may, for example, be carried out on a tonne scale. After blending, the composition is divided into smaller portions for packaging into dosage amounts.
  • the invention thus provides a method comprising the step of dividing bulk composition as set out in section 5e) above into smaller portions.
  • the invention also provides a method comprising the step of filling containers with individual dosage amounts of bulk composition as set out in section 5e).
  • the invention thus provides a method comprising the step of filling a container with a composition as set out in section 5d).
  • the composition as set out in section 5d) may be presented in two or more parts.
  • the method may thus comprise the step of filling a container with some but not all of the components of a composition as set out in section 5d).
  • the solutions and compositions of the first and second aspects of the invention set out in sections 2 to 5 above find particular use in split dose colon cleansing treatments in which the subject takes two different agents (for example two different solutions): a first colon cleansing agent (for example solution), followed by a second colon cleansing agent (for example solution).
  • the “second colon cleansing agent” means the agent that is taken chronologically second, after the “first colon cleansing agent”.
  • the solution of the first or second aspect of the invention is the second colon cleansing agent.
  • it may be the first agent.
  • the invention thus provides, in a third aspect a method of cleansing the colon of a mammal comprising:
  • the second colon cleansing agent being a solution of the first or second aspect of the invention described above.
  • the first colon cleansing agent is of different composition from the second colon cleansing agent. Details of the regimens in which the method may be carried out are described in further detail in section 3c) above.
  • the first colon cleansing agent may be a colon cleansing solution. Alternatively, it may be a colon cleansing agent in solid form, for example in the form of a tablet, for example a PEG-containing tablet, or a bisacodyl-containing tablet.
  • the first colon cleansing agent may, for example, contain a laxative, for example a stimulant laxative. For example, bisacodyl, castor oil, senna or bisoxatin may be used.
  • the invention also provides a method of cleansing the colon of a mammal comprising:
  • the invention also provides a method of cleansing the colon of a mammal comprising:
  • the second colon cleansing agent being a solution comprising
  • the method of the invention may be used to cleanse the colon prior to carrying out a diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen.
  • the diagnostic or surgical procedure may, for example, be colonoscopy, barium enema examination, sigmoidoscopy or colon surgery.
  • the method of the invention is generally finished less than 8 hours before carrying out the diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen. Preferably, it is finished less than 4 hours before.
  • the invention further provides a method of conducting a diagnostic or surgical procedure, for example, a colonoscopy, barium enema examination, sigmoidoscopy or colon surgery, comprising the steps of:
  • the invention further provides a first colon cleansing agent, and a second colon cleansing agent, for use in a method of cleansing the colon comprising:
  • the second colon cleansing agent being a solution of the first or second aspect of the invention described above.
  • the invention further provides a first colon cleansing agent, and a second colon cleansing agent, for use in a method of cleansing the colon comprising:
  • the subject taking an effective amount of a second colon cleansing agent, the second colon cleansing agent being a solution in water of:
  • the first agent is different from the second.
  • the invention further provides a first colon cleansing agent, and a second colon cleansing agent, for use in a method of cleansing the colon comprising:
  • the subject taking an effective amount of a second colon cleansing agent, the second colon cleansing agent being a solution in water of:
  • the solution being essentially free from ascorbic acid.
  • the first agent is different from the second. Further details of possible first colon cleansing agents are provided below in section 6b)
  • the second colon cleansing agent is preferably as described hereinabove in sections 2 to 5 in relation to solutions and uses of the first and second aspects of the invention. It is preferably used in a volume as described hereinabove in relation to solutions and uses of the invention as described hereinabove in sections 2 to 5.
  • the first and second colon cleansing agents may be provided in a kit. Further details of such kits are provided in section 8) below.
  • the first cleansing agent may be a solution, referred to as the first colon cleansing solution.
  • the first colon cleansing solution may, for example, be a bowel content suspending agent.
  • the first colon cleansing solution may comprise polyethylene glycol and/or an alkali metal sulphate, an alkaline earth metal sulphate or a mixture thereof.
  • the first colon cleansing solution may be hyper-osmotic.
  • the first colon cleansing solution comprises polyethylene glycol (PEG).
  • the polyethylene glycol (PEG) may have an average molecular weight of 2000 to 8000, for example 2500 to 4500 Da, for example 2680 to 4020 Da, for example 3000 to 4000 Da.
  • the PEG may be PEG 3350 or PEG 4000 as defined in national pharmacopeias.
  • PEG8000 may also be used.
  • suitable PEGs recognized in some national pharmacopeias include Macrogols, for example Macrogol 3350 or Macrogol 4000.
  • the first colon cleansing solution comprises 70 to 250 g per litre of PEG.
  • the solution comprises 130 to 250 g per litre PEG, for example 90 to 200 g per litre of PEG, more preferably 100 to 200 g per litre, for example 120 to 150 g per litre, for example 133.3 g per litre; for example 150 to 250 g per litre, for example 175 to 225 g per litre, for example 200 g per litre.
  • the first colon cleansing solution comprises one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof (herein referred to as a “sulphate component”).
  • An alkali metal or alkaline earth metal sulphate may, for example, be selected from sodium sulphate, potassium sulphate and magnesium sulphate.
  • the solution may comprise more than one of sodium sulphate, potassium sulphate and magnesium sulphate, for example all three.
  • the sulphate component is or includes sodium sulphate.
  • the first colon cleansing solution comprises a sulphate component (for example sodium sulphate) at a concentration of 2 to 20 g per litre, for example 2 to 15 g per litre, for example 5 to 15 g per litre, for example 8 to 12 g per litre, for example 8 or 12 g per litre; for example 10 to 20 g per litre, for example 15 to 20 g per litre, for example 17 to 19 g per litre, for example 18 g per litre.
  • the first colon cleansing solution comprises 8.0 to 20 g per litre of one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof.
  • the first colon cleansing solution may comprise:
  • flavouring agents optionally one or more flavouring agents
  • the first colon cleansing solution may comprise one or more electrolytes.
  • Electrolytes include salts of sodium, potassium, calcium and magnesium, particularly sodium and potassium; and salts of chloride, iodide, bicarbonate and carbonate, particularly chloride.
  • Preferred electrolytes are sodium chloride and potassium chloride.
  • sodium bicarbonate is not included.
  • the first colon cleansing solution may comprise sodium chloride at a concentration of 0.5 to 5.0 g per litre.
  • sodium chloride may be present at a concentration of 1.0 to 4.0 g per litre, for example 1.0 to 3.0 g per litre, for example 1.5 to 3.0 g per litre, for example 2.0 to 3.0 g per litre; for example 3.0 to 5.0 g per litre, for example 3.5 to 4.5 g per litre, for example 4.0 g per litre.
  • the first colon cleansing solution may comprise potassium chloride at a concentration of 1 to 10 g per litre.
  • potassium chloride may be present at a concentration of 0.05 to 5.0 g per litre, for example 0.1 to 3.0 g per litre, for example 0.2 to 2.0 g per litre, for example 0.5 to 1.5 g per litre, for example 0.5 to 1.1 g per litre; for example 1.5 to 2.5 g per litre, for example 1.8 to 2.2 g per litre, for example 2.0 g per litre.
  • the first colon cleansing solution comprises sodium chloride and potassium chloride. They can be present in the amounts mentioned immediately above.
  • sodium chloride may be present at a concentration of 1.0 to 3.0 g per litre and potassium chloride may be present at a concentration of 2.5 to 3.0 g per litre; for example, sodium chloride may be present at a concentration of 3.0 to 5.0 g per litre and potassium chloride may be present at a concentration of 0.5 to 1.1 g per litre.
  • the first colon cleansing solution comprises sodium chloride and potassium chloride. They can be present in the amounts mentioned immediately above.
  • sodium chloride may be present at a concentration of 1.5 to 3.0 g per litre and potassium chloride may be present at a concentration of 0.2 to 2.0 g per litre; for example, sodium chloride may be present at a concentration of 3.0 to 5.0 g per litre and potassium chloride may be present at a concentration of 1.5 to 2.5 g per litre.
  • the first colon cleansing solution comprises:
  • flavouring agents optionally one or more flavouring agents
  • the first colon cleansing solution may be a solution as commercialised under the tradename MOVIPREP® or a solution as commercialised under the tradename SUCLEAR®.
  • the first colon cleansing solution preferably includes a flavouring agent.
  • the first colon cleansing solution preferably includes a sweetener.
  • Flavouring agents and sweeteners may be as described hereinabove.
  • a flavouring for use in in the first colon cleansing solution should preferably mask saltiness, be relatively sweet but not excessively so, and be stable in the composition.
  • a flavouring makes the solutions more palatable and thus aids patient compliance.
  • Preferred flavourings include lemon e.g. Ungerer Lemon (available from Ungerer Limited, Sealand Road, Chester, England CH1 4LP) strawberry e.g. Ungerer Strawberry, grapefruit e.g. Ungerer Grapefruit flavouring powder, blackcurrant e.g. Ungerer Blackcurrant, pineapple e.g. IFF (International Flavours and Fragrances) Pineapple flavouring powder, orange eg Firmenich Orange, and vanilla/lemon and lime e.g.
  • flavourings are available from International Flavours and Fragrances Inc. (Duddery Hill, Haverhill, Suffolk, CB9 8LG, England), Ungerer & Company (Sealand Road, Chester, England CH1 4LP) or Firmenich (Firmenich UK Ltd., Hayes Road, Southall, Middlesex UB2 5NN). More preferred flavourings are lemon, kiwi, strawberry grapefruit, fruit punch and mango. Fruit punch and mango are especially preferred flavours.
  • a particularly preferred flavouring is fruit punch flavour, for example at a level of 0.4 to 3.5 g per litre, for example 0.4 to 1.2 g per litre, for example 0.938, 1.0 or 3.18 g per litre.
  • the first cleansing solution preferably includes a sweetener.
  • Preferred sweeteners include aspartame, acesulfame potassium (acesulfame K), sucralose and saccharine, and/or combinations thereof.
  • the solution may comprise one or both of aspartame and acesulfame potassium (acesulfame K).
  • it may comprise one or both of sucralose and acesulfame potassium (acesulfame K).
  • the solution comprises aspartame or sucralose, for example sucralose.
  • Preferred sweeteners include aspartame, acesulfame potassium (acesulfame K), sucralose and saccharine, and/or combinations thereof.
  • compositions of the invention may comprise one or both of aspartame and acesulfame potassium (acesulfame K).
  • compositions of the invention may comprise one or both of sucralose and acesulfame potassium (acesulfame K).
  • the solution comprises aspartame or sucralose, for example aspartame.
  • compositions of the invention can be essentially free from added sweeteners, for example to minimize the number of different components in the compositions.
  • a souring agent for example citric acid
  • a souring agent is a component that imparts a sourness to a composition.
  • Other souring agents include malic acid, acetic acid, tartaric acid, gluconodeltalactone, phosphoric acid, succinic acid, phytic acid, lactic acid or salts thereof. It may be present at a level of from 0.1 to 3.0 g per litre, for example 0.3 to 2.0 g per litre, for example 0.5 to 2.0 g per litre, for example 0.75 g, 1.0 g, 1.06 g, 1.25 g or 1.5 g per litre.
  • the souring agent for example citric acid
  • the souring agent may be provided in an encapsulated form.
  • the encapsulation provides a coating that isolates the souring agent from other components and from air and moisture prior to its use.
  • Several encapsulated forms of citric acid, or other souring agents, are commercially available.
  • the encapsulation may be with a water-soluble coating.
  • the amount of sweetener required depends on the nature and strength of the sweetener being considered. Typically, it is 0.10 to 4 g per litre.
  • the sweetener may be sucralose at 0.1 to 3.0 g per litre, for example 0.3 to 2.0 g per litre, for example 0.5 to 2.0 g per litre, for example 0.5 to 1.3 g per litre for example 0.63 g, 0.80 g, 1.0 g or 1.58 g per litre.
  • the first cleansing solution may include one or more further optional components. Such components may be as set out above in section 3b).
  • the first colon cleansing solution has a volume of from 400 to 600 ml (for example 500 ml), and contains the quantities of solutes described in the section immediately above.
  • the volume may be 16 or 17 US fluid ounces.
  • the invention provides colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • Such a solution has a smaller volume than cleansing solutions that are generally used.
  • the first colon cleansing solution is provided in a volume of from 300 ml up to 1200 ml.
  • the first solution may have a volume in a range with a lower limit of 300 ml, 400 ml, 500 ml, 600 ml or 700 ml.
  • the lower limit is 500 ml, 600 ml or 700 ml.
  • the volume may be in a range with an upper limit of 1200 ml, 1100 ml, 1000 ml, 900 ml or 800 ml.
  • the volume may be in the range 400 ml to 1100 ml, for example 500 ml to 1000 ml, for example 600 ml to 900 ml, for example 700 ml to 800 ml.
  • the first colon cleansing solution is provided in a volume of 750 ml.
  • the volume may be in the range 400 ml to 600 ml.
  • the first colon cleansing solution is provided in a volume of 500 ml.
  • it may be in a volume of 16 or 17 US fluid ounces.
  • the most appropriate volume will depend on the exact components of the solution and the amounts in which they are present. In general, for a solution of higher osmotic strength, a smaller volume will be required.
  • the first cleansing solution may, for example, have a measured osmolality in the range 200 to 2000 mOsmol/kg, 200 to 1500 mOsmol/kg. In a preferred embodiment, it is hyper-osmotic. It may, for example have a measured osmolality in the range 320 to 1500 mOsmol.
  • the measured osmolality of the first cleansing solution is in the range 330 to 1200 mOsmol/kg, for example 340 to 1000 mOsmol/kg, for example 350 to 800 mOsmol/kg, for example 350 to 700 mOsmol/kg.
  • the solutes in the solution may have a V(350) value of from 800 to 1600 ml, for example from 1000 to 1400 ml, for example from 1150 to 1250 ml, and be in a volume of 400 to 600 ml, for example 500 ml.
  • the invention further provides a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution.
  • the composition may comprise:
  • flavouring agents optionally one or more flavouring agents
  • composition may comprise:
  • flavouring agents optionally one or more flavouring agents
  • the flavouring and sweetener may be 0.469 g fruit punch flavouring, 0.476 g sucralose and 0.792 g citric acid.
  • the flavouring and sweetener may be 0.500 g fruit punch flavouring, 0.40 g sucralose and 0.75 g citric acid.
  • the flavouring and sweetener may be 1.43 g mango flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • the flavouring and sweetener may be 1.59 g fruit punch flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • Citric acid may optionally be packaged separately from the other components.
  • the cleansing solution of S2 is administered to the subject before the cleansing solution of T1 is administered. It is particularly preferred that S2 is administered to the subject and then, following a time interval (such as disclosed herein), T1 is administered to the subject.
  • additional fluid such as clear fluid
  • additional clear fluid is administered to the subject in conjunction with S2 and/or T1.
  • additional clear fluid such as 500 ml or thereabout, or 1000 ml or thereabout
  • additional clear fluid is administered to the subject during administration of S2 and/or T1.
  • the cleansing solution of S2 and/or T1 is self-administered.
  • a sulphate-containing colon cleansing solution that contains a souring agent (for example citric acid) and sucralose is particularly palatable.
  • the invention further provides, according to a fourth aspect, a colon cleansing solution comprising:
  • (iii 2) optionally 0.5 to 1.5 (for example 0.5 to 1.1) g per litre potassium chloride;
  • flavouring agents optionally one or more flavouring agents
  • the invention provides a method for improving the palatability of a sulphate-containing colon cleansing solution comprising including in the solution 0.1 to 3.0 g per litre sucralose and 0.1 to 4.0 g per litre of souring agent, for example 0.1 to 3.0 g per litre of souring agent, for example citric acid.
  • the invention provides a method for diminishing the poor taste of a sulphate-containing colon cleansing solution comprising including in the solution 0.1 to 3.0 g per litre sucralose and 0.1 to 4.0 g of souring agent, for example 0.1 to 3.0 g per litre of souring agent, for example citric acid.
  • the improved palatability is associated with a reduced perceived saltiness of the solutions.
  • the invention thus provides a method for reducing the perceived saltiness of a sulphate-containing colon cleansing solution comprising including in the solution 0.1 to 3.0 g per litre sucralose and 0.1 to 4.0 g per litre of souring agent, for example 0.1 to 3.0 g per litre of souring agent, for example citric acid. “Reduction” here is taken to mean as compared with an equivalent solution without the sucralose and souring agent.
  • a souring agent may be selected from citric acid, malic acid, acetic acid, tartaric acid, gluconodeltalactone, phosphoric acid, succinic acid, phytic acid, lactic acid or salts thereof.
  • the souring agent may be citric acid. It may be present at a level of from 0.1 to 4.0 g per litre, for example 0.1 to 3.0 g per litre, for example 0.3 to 2.0 g per litre, for example 0.5 to 2.0 g per litre, for example 0.75 g, 1.0 g, 1.06 g, 1.25 g or 1.5 g per litre. For example, it may be at a level of 3.0 to 4.0 g per litre, for example 3.48 g per litre.
  • Citric acid may be provided in an encapsulated form.
  • the encapsulation provides a coating that isolates the souring agent from other components and from air and moisture prior to its use.
  • Several encapsulated forms of citric acid, or other souring agents, are commercially available.
  • the encapsulation may be with a water-soluble coating.
  • the sucralose may, for example be present at a level of 0.1 to 3.0 g per litre, for example 0.3 to 2.0 g per litre, for example 0.5 to 2.0 g per litre, for example 0.5 to 1.3 g per litre for example 0.63 g, 0.80 g, or 1.0 g per litre. For example, it may be at a level of 1.58 g per litre.
  • a particularly preferred flavouring is fruit punch flavour, for example at a level of 0.4 to 1.2 g per litre, for example 0.625 g per litre or 1.0 g per litre.
  • compositions for the preparation of such a solution for example by admixture with water.
  • Preferred amounts of each of components (i) to (iv) in the solutions and compositions of the fourth aspect of the invention are as set out for the first colon cleansing solutions and first colon cleansing compositions hereinabove in section 6b).
  • a colon cleansing solution according to the fourth aspect of the invention may contain PEG, sulphate, sodium chloride, potassium chloride and flavouring in amounts and types as described hereinabove in relation to the first colon cleansing solution in section 6b).
  • a colon cleansing solution according to the fourth aspect of the invention may be used together with a solution of the first or second aspect of the invention as set out in sections 2 to 5. Alternatively, it may be used in combination with a different other colon cleansing solution, or used in a suitable volume on its own. If used on its own, it may be used in a single dose or in a split dose administration.
  • the invention provides a method of cleansing the colon of a subject comprising administering a solution of the fourth aspect of the invention.
  • the solution may be administered on its own or in combination with a further, different, solution.
  • the invention provides a composition for admixture with water (for example a dry composition, for example a powder), wherein the composition is optionally presented in two or more parts and comprises the components of a solution of the invention. If the components are provided in two or more parts, they may be provided in a kit.
  • the invention thus provides a kit comprising:
  • the kit may further comprise additional components as set out in sections 3a), 3b) and 3d) above, and in the amounts set out there.
  • the kit may contain:
  • flavouring agents optionally one or more flavouring agents
  • Each of c) and d) may be present in the amounts described in section 3a) and 3d) above.
  • Each of e) and f) may be as described above and/or be in the amounts described in section 3a) and 3d) above.
  • the kit contains:
  • flavouring agents e) one or more flavouring agents
  • the ascorbate component a) is packaged separately from the PEG component b).
  • the remaining elements may be packaged together with the PEG component.
  • the flavouring component e) or the sweetener component f) may be provided separately from other components.
  • the kit may provide several alternative flavourings, allowing the subject to decide themselves which flavouring from a range of flavourings to use.
  • the kit may contain:
  • flavouring agents e) one or more flavouring agents
  • component a) is packaged in a first compartment and components b), c) e) and f) are packaged in a second compartment.
  • One or more of the components may be in a dry powder form (for example the ascorbate component or the PEG component may be in dry powder form), whilst some of the remaining components (for example the sodium chloride or the potassium chloride) are in the form of a tablet or in a semi-solid (for example gel) form.
  • the subject may be instructed to dissolve the powder components in water and drink it, and instructed to take the tablet or semi-solid form without dissolution.
  • a semi-solid form for example gel
  • the subject may be instructed to add it to water before ingesting it, or the subject may be instructed to take it as provided.
  • the invention provides a composition for admixture with water (for example a dry composition, for example a powder), wherein the composition is optionally presented in two or more parts and comprises the components of a solution of the invention. If the components are provided in two or more parts, they may be provided in a kit.
  • the invention thus provides a kit comprising:
  • the kit being essentially free from ascorbic acid.
  • the kit may further comprise additional components as set out in sections 5a), 5b) and 5d) above, and in the amounts set out there.
  • the kit may contain:
  • flavouring agents optionally one or more flavouring agents
  • the kit being essentially free from ascorbic acid.
  • Each of c) and d) may be present in the amounts described in section 5a) and 5d) above.
  • Each of e) and f) may be as described above and/or be in the amounts described in section 5a) and 5d) above.
  • the kit contains:
  • flavouring agents e) one or more flavouring agents
  • kits f) one or more sweeteners; the kit being essentially free from ascorbic acid.
  • the ascorbate component a) is packaged separately from the PEG component b).
  • the remaining components may be packaged together with the PEG component.
  • the flavouring component e) or the sweetener component f) may be provided separately from other components.
  • the kit may provide several alternative flavourings, allowing the subject to decide themselves which flavouring from a range of flavourings to use.
  • the kit may contain:
  • flavouring agents e) one or more flavouring agents
  • component a) is packaged in a first compartment and components b), c) e) and f) are packaged in a second compartment.
  • one or more of the components may be in a dry powder form (for example the ascorbate component or the PEG component may be in dry powder form), whilst some of the remaining components (for example the sodium chloride or the potassium chloride) are in the form of a tablet or in a semi-solid (for example gel) form.
  • the subject may be instructed to dissolve the powder components in water and drink it, and instructed to take the tablet or semi-solid form without dissolution. If a semi-solid form (for example gel) is present, the subject may be instructed to add it to water before ingesting it, or the subject may be instructed to take it as provided.
  • kits of the invention may be provided in the form of, for example, a box.
  • the kit may be provided in a package, or example an envelope (which may be addressed to the subject), for example a padded envelope.
  • the box or other package containing the kit may, for example, be one that can be posted into a standard domestic mailbox, so that it can conveniently be sent to a subject in the mail. In the USA, that typically means that a box fits into a slot 1.75 inches high by 10 inches wide. In Europe, the minimum mailbox aperture width is generally 230 mm and the minimum height is 30 mm.
  • the first and/or second parts may each contained in one or more containers. Examples of suitable containers include tubs, bags and sachets. A preferred container is a sachet.
  • the composition of the invention can be provided in a multi-chambered container, for example of the type disclosed in WO2012/105524.
  • a multi-chambered container may have a partition wall and two separate powders can be stored separated from each other.
  • a powdered medicine which has been stored in a separated state, can be simply and readily mixed at the time of use to provide an aqueous solution.
  • a multi-chambered container comprises a substantially flat pouch formed from a flexible film, a partition wall configured as a detachable seal detachably welding opposing inner surfaces of the pouch, and a pour port for infusion and discharge of a liquid, that is attached to the periphery of the pouch so as to open into one of the plurality of partitioned chambers.
  • the partition wall comprises a horizontal section which extends along a gusseted bottom section of the pouch and a perpendicular section which is curved from the horizontal section to a pouch upper section.
  • the partition wall may, for example, be frangible.
  • a first partitioned chamber having a large capacity is formed on one side of the partition wall close to the bottom section of the pouch
  • a second partitioned chamber having a small capacity is formed on the other side of the partition wall
  • the pour port opens into the first partitioned chamber.
  • the invention provides various split-dose treatments for colon cleansing in which the subject takes two different agents.
  • the invention thus provides a kit comprising:
  • the second colon cleansing agent being a solution of the first or second aspect of the invention described above.
  • the invention provides a kit comprising:
  • the second colon agent solution being a solution in water of:
  • the invention also provides a kit comprising:
  • the second colon cleansing agent being a solution in water of:
  • the solution being essentially free from ascorbic acid.
  • the first agent is different from the second.
  • kits of the invention may provide compositions for the preparation of the colon cleansing solutions.
  • the invention thus further provides a kit comprising:
  • A) a first component being a composition, optionally presented in two or more parts for the preparation of a first colon cleansing solution as described above by admixture with water;
  • a second component being a composition, optionally presented in two or more parts for the preparation of a second colon cleansing solution by admixture with water, the second colon cleansing solution being a solution as described hereinabove in relation to solutions and uses of the first or second aspects of the invention as set out in sections 2 to 5.
  • the first solution is of different composition from the second.
  • kit of the invention may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • B) a second component being a composition optionally presented in two or more parts for the preparation of a second colon cleansing solution, comprising
  • a kit of the invention may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • B) a second component being a composition optionally presented in two or more parts for the preparation of a second colon cleansing solution, comprising
  • the first solution being different from the second.
  • the first component may be a composition for the preparation of a solution as set out in section 6b) above.
  • the first component preferably comprises 97.5 to 187.5 g of PEG, for example 67.5 to 150 g of PEG, more preferably 75 to 150 g, for example 90 to 112.5 g, for example 100 g PEG.
  • the first component comprises a sulphate component (for example sodium sulphate) in an amount of 1.5 to 11.25 g, for example 3.75 to 11.25 g, for example 6 to 9 g, for example 6 or 9 g.
  • a sulphate component for example sodium sulphate
  • the first component comprises 6.0 to 15 g of one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof.
  • it comprises 9 g of sodium sulphate.
  • the first component comprises sodium chloride in an amount of 0.375 to 3.75 g.
  • sodium chloride may be present in an amount of 0.75 to 3.0 g, for example 0.75 to 2.25 g, for example 1.125 to 2.25 g, for example 1.5 to 2.25 g, for example 2.0 g.
  • the first component comprises potassium chloride in an amount of 0.75 to 7.5 g.
  • potassium chloride may be present in an amount of 0.0375 to 3.75 g, for example 0.075 to 2.25 g, for example 0.15 to 1.5 g, for example 0.375 to 1.125 g, for example 0.375 to 0.825 g, for example 1.0 g.
  • the first component comprises sodium chloride and potassium chloride. They can be present in the amounts mentioned immediately above.
  • sodium chloride may be present in an amount of 1.125 to 2.25 g and potassium chloride may be present in an amount of 0.15 to 1.5 g; for example 2.0 g sodium chloride and 1.0 g potassium chloride.
  • the second component of the kit of compositions of the invention is preferably a composition for the preparation of a solution of the first or second aspect of the invention as described hereinabove in sections 3 or 5.
  • the kit may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • B) a second component being a composition optionally presented in two or more parts for the preparation of a second colon cleansing solution, comprising
  • flavouring agents e) one or more flavouring agents
  • component B) in component B) the ascorbate component a) is packaged separately from the PEG component b). The remaining elements of component B) may be packaged together with the PEG component.
  • a kit may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • flavouring agents e) one or more flavouring agents
  • component a) is packaged in a first compartment and components b), c) e) and f) are packaged in a second compartment.
  • the flavouring and sweetener in the first component may be 0.469 g fruit punch flavouring, 0.476 g sucralose and 0.792 g citric acid.
  • the flavouring and sweetener may be 0.500 g fruit punch flavouring, 0.40 g sucralose and 0.75 g citric acid.
  • the flavouring and sweetener may be 1.43 g mango flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • the flavouring and sweetener may be 1.59 g fruit punch flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • Citric acid may optionally be packaged separately from the other components.
  • the flavouring and sweetener in the second component may be 0.60 g orange flavour and 1.93 g aspartame.
  • the flavouring and sweetener may be 1.60 g citrus flavour and 0.875 g aspartame.
  • the flavouring and sweetener may be 2.10 g orange grapefruit flavour and 0.875 g aspartame.
  • the kit may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • B) a second component being a composition optionally presented in two or more parts for the preparation of a second colon cleansing solution, comprising
  • flavouring agents e) one or more flavouring agents
  • component B) in component B) the ascorbate component a) is packaged separately from the PEG component b). The remaining elements of component B) may be packaged together with the PEG component.
  • a kit may comprise:
  • A) a first component being a composition optionally presented in two or more parts for the preparation of a first colon cleansing solution comprising:
  • flavouring agents optionally one or more flavouring agents
  • flavouring agents e) one or more flavouring agents
  • component a) is packaged in a first compartment and components b), c) e) and f) are packaged in a second compartment.
  • the flavouring and sweetener in the first component may be 0.469 g fruit punch flavouring, 0.476 g sucralose and 0.792 g citric acid.
  • the flavouring and sweetener may be 0.500 g fruit punch flavouring, 0.40 g sucralose and 0.75 g citric acid.
  • the flavouring and sweetener may be 1.43 g mango flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • the flavouring and sweetener may be 1.59 g fruit punch flavouring, 0.79 g sucralose and 1.74 g citric acid.
  • Citric acid may optionally be packaged separately from the other components.
  • the flavouring and sweetener in the second component may be 0.80 g orange flavour and 1.10 g aspartame.
  • the flavouring and sweetener may be 1.60 g lemon/lime flavour and 1.625 g aspartame.
  • the flavouring and sweetener may be 2.15 g orange grapefruit flavour and 1.625 g aspartame.
  • kits of the invention has instructions that instruct the user of the volume to which each component is to be made up with water.
  • the specified volume of water for each solution is less than one litre.
  • the specified volume for the first component may be 300 ml to 1200 ml, for example 600 ml to 900 ml, for example 750 ml; for example it may be a volume of 25 or 26 US fluid ounces, for example 400 to 600 ml, for example 500 ml.
  • it may be a volume of 16 or 17 US fluid ounces.
  • the specified volume for the second component may be from 250 ml to 1000 ml, for example 400 ml to 700 ml, for example 500 ml.
  • it may be a volume of 16 or 17 US fluid ounces.
  • Further volumes that may be specified in the instructions are the volumes set out hereinabove in relation to the methods of the invention.
  • the instructions specify that the first and second solutions are to be ingested in succession with a time interval between them.
  • the instructions specify that the first cleansing solution is ingested first followed, after a time interval (for example the time between an evening and the following morning) by ingestion of the second cleansing solution.
  • the time interval is preferably as described above in relation to the methods of the invention.
  • the instructions may specify that the components in the kit be made up into solutions and then taken in accordance with the description set out above in section 6 for the first solution and sections 3c) and 5c) for the second solution.
  • components A) and B) may be in dry powder, granular or other dry form. They may alternatively be in the form of concentrates or slurries. Components A) and B) may be in the same or different physical forms. Components within A) and B) may be in the same or different physical forms. For example, one or both of components A) and B) are dry powders. A portion of either or each of components A) and B) may be in the form of one or more solid tablets or capsules.
  • kits of the invention may each contained in one or more containers.
  • the second component may be contained in more than one container.
  • the second component comprises both ascorbic acid and PEG then the ascorbic acid and PEG may be contained in separate containers.
  • the other constituents of the second component may be in either of the separate containers. For example, they may be in the container containing the PEG.
  • flavouring component is present in the first or second solution, then in a kit of the invention, the flavouring component for the relevant solution may be provided in a separate container from the other constituents of that solution.
  • suitable containers include tubs, bags and sachets.
  • a preferred container is a sachet.
  • composition of the invention can be provided in a multi-chambered container, for example of the type disclosed in WO2012/105524, as described above in section 8a).
  • a kit comprises:
  • the first sachet comprises polyethylene glycol and/or sodium sulphate
  • the second sachet comprises one or more components selected from polyethylene glycol, one or more alkali metal sulphates, alkaline earth metal sulphates or a mixture thereof and electrolytes; and
  • the third sachet comprises one or more salts of ascorbic acid and, if appropriate, ascorbic acid;
  • kits of the invention rather than being provided within a first sachet (A) with the PEG, some or all of the sulphate(s), electrolytes, flavouring agents and sweeteners are provided in the form of a tablet or capsule.
  • a kit of the invention rather than being provided within a second or third sachet (B1 or B2) with the PEG, ascorbic acid or ascorbate component, some or all of the sulphate(s), electrolytes, flavouring agents and sweeteners are provided in the form of a tablet or capsule.
  • a kit may contain one treatment, for example a cleansing treatment, or several treatments.
  • a treatment generally comprises one dose of the first cleansing solution (or components for preparing the first cleansing solution) and one dose of the second cleansing solution (or components for preparing the first cleansing solution).
  • the first component comprises one dose of the first cleansing solution
  • the second component comprises one dose of the second cleansing solution.
  • a kit of the invention may be for use in a method of cleansing the colon comprising:
  • the solutions and compositions of the first and second aspects of the invention described above in sections 2 to 5 find further use in split dose colon cleansing treatments in which the subject takes two different solutions (a first colon cleansing solution, followed by a second colon cleansing solution) in which the solution of the first or second aspect of the invention is the first colon cleansing solution.
  • the invention thus provides a method of cleansing the colon of a mammal comprising:
  • the first colon cleansing solution being a solution of the first or second aspect of the invention described above in sections 2 to 5.
  • the invention also provides a method of cleansing the colon of a mammal comprising:
  • the first colon cleansing solution being a solution comprising
  • the invention also provides a method of cleansing the colon of a mammal comprising:
  • the solution being essentially free from ascorbic acid.
  • solutions and methods of the fifth aspect of the invention may have the features described above in relation to the solutions and methods of the third aspect of the invention as set out in section 6 above.
  • the invention also provides a method of cleansing the colon of a subject comprising:
  • the first cleansing solution is hyper-osmotic and contains ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof (for example ascorbic acid and sodium ascorbate, for example sodium ascorbate); and wherein the second cleansing solution is either substantially free from ascorbic acid and salts thereof, or contains ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof, in an amount providing a lower concentration of ascorbate anion than is present in the first cleansing solution.
  • the first cleansing solution may comprise PEG and electrolytes (for example sodium chloride and potassium chloride).
  • the second solution may comprise PEG; it may comprise an alkali metal or alkaline earth metal sulphate (for example sodium sulphate); it may comprise electrolytes (for example sodium chloride and potassium chloride).
  • kits comprising a first and a second solution according to the invention, and kits comprising compositions for preparing the first and second solutions.
  • the first cleansing solution contains a higher concentration of ascorbate anion than is present in the second cleansing solution.
  • the first cleansing solution contains twice the concentration of the ascorbate anion than the second cleansing solution or more.
  • the first solution contains three times or more, four times or more, or five times or more the concentration of the ascorbate anion than the second cleansing solution.
  • the first cleansing solution contains a concentration of the ascorbate anion that is at least 50 mmol per litre greater than that of the second cleansing solution.
  • the first solution contains a concentration of ascorbate anion that is at least 50 mmol per litre greater than that of the second solution.
  • the first solution contains a concentration of the ascorbate anion that is greater by at least 100 mmol per litre, for example at least 200 mmol per litre, at least 300 mmol per litre.
  • the second cleansing solution may be substantially free from an ascorbate component.
  • the first cleansing solution may comprise:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US14/202,098 2012-09-11 2014-03-10 Compositions Abandoned US20140186470A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
US14/202,098 US20140186470A1 (en) 2012-09-11 2014-03-10 Compositions
EA201600639A EA037891B1 (ru) 2014-03-10 2015-03-09 Способ очищения толстой кишки
ES15709665T ES2831412T3 (es) 2012-09-11 2015-03-09 Composiciones que comprenden PEG y ascorbato
KR1020167027883A KR102234803B1 (ko) 2014-03-10 2015-03-09 대장 세척 방법
PCT/EP2015/054856 WO2015135880A1 (en) 2014-03-10 2015-03-09 Method of cleansing the colon
CN202210809414.3A CN115154464A (zh) 2012-09-11 2015-03-09 清洗结肠的方法
PL20189946.5T PL3777850T3 (pl) 2014-03-10 2015-03-09 Sposób oczyszczania okrężnicy
AU2015228962A AU2015228962B2 (en) 2014-03-10 2015-03-09 Method of cleansing the colon
SG11201606834QA SG11201606834QA (en) 2014-03-10 2015-03-09 Method of cleansing the colon
NZ723017A NZ723017B2 (en) 2015-03-09 Method of cleansing the colon
MYPI2016703268A MY188550A (en) 2014-03-10 2015-03-09 Method of cleansing the colon
PT201899465T PT3777850T (pt) 2014-03-10 2015-03-09 Método de limpeza do cólon
MX2016011256A MX2016011256A (es) 2012-09-11 2015-03-09 Metodo para el lavado del colon.
CN201580013447.5A CN106102738A (zh) 2012-09-11 2015-03-09 清洗结肠的方法
UAA201610268A UA123659C2 (uk) 2014-03-10 2015-03-09 Спосіб очищення товстої кишки
SG10201807427RA SG10201807427RA (en) 2012-09-11 2015-03-09 Method of cleansing the colon
DK20189946.5T DK3777850T3 (da) 2014-03-10 2015-03-09 Fremgangsmåde til rensning af colon
CA2942089A CA2942089C (en) 2014-03-10 2015-03-09 Method of cleansing the colon
BR112016019914A BR112016019914A8 (pt) 2014-03-10 2015-03-09 método de limpeza do cólon de um indivíduo antes de um procedimento diagnóstico, terapêutico ou cirúrgico e uso
EP20189946.5A EP3777850B1 (en) 2014-03-10 2015-03-09 Method of cleansing the colon
MX2021005225A MX2021005225A (es) 2014-03-10 2015-03-09 Método para el lavado del colon.
ES20189946T ES2928719T3 (es) 2014-03-10 2015-03-09 Procedimiento de limpieza del colon
EP15709665.2A EP3116494B8 (en) 2014-03-10 2015-03-09 Method of cleansing the colon
US14/954,290 US20160184263A1 (en) 2012-09-11 2015-11-30 Compositions
IL247170A IL247170B (en) 2014-03-10 2016-08-08 Colon lavage method
ZA2016/05592A ZA201605592B (en) 2014-03-10 2016-08-12 Method of cleansing the colon
US15/605,617 US10918723B2 (en) 2012-09-11 2017-05-25 Colon cleansing compositions and methods of use
IL274374A IL274374A (en) 2014-03-10 2020-04-30 Colon cleansing solution

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261699488P 2012-09-11 2012-09-11
US201361787366P 2013-03-15 2013-03-15
PCT/EP2013/068738 WO2014040994A1 (en) 2012-09-11 2013-09-10 Compositions comprising peg and ascorbate
US14/202,098 US20140186470A1 (en) 2012-09-11 2014-03-10 Compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/068738 Continuation-In-Part WO2014040994A1 (en) 2012-09-11 2013-09-10 Compositions comprising peg and ascorbate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/954,290 Continuation US20160184263A1 (en) 2012-09-11 2015-11-30 Compositions

Publications (1)

Publication Number Publication Date
US20140186470A1 true US20140186470A1 (en) 2014-07-03

Family

ID=49165735

Family Applications (9)

Application Number Title Priority Date Filing Date
US14/202,098 Abandoned US20140186470A1 (en) 2012-09-11 2014-03-10 Compositions
US14/223,127 Active US8999313B2 (en) 2012-09-11 2014-03-24 Compositions
US14/657,495 Active US9326969B2 (en) 2012-09-11 2015-03-13 Compositions
US14/954,290 Abandoned US20160184263A1 (en) 2012-09-11 2015-11-30 Compositions
US15/141,054 Active 2033-10-19 US9707297B2 (en) 2012-09-11 2016-04-28 Compositions
US15/454,132 Active US10016504B2 (en) 2012-09-11 2017-03-09 Compositions
US15/605,617 Active 2033-09-15 US10918723B2 (en) 2012-09-11 2017-05-25 Colon cleansing compositions and methods of use
US16/028,819 Abandoned US20180311361A1 (en) 2012-09-11 2018-07-06 Compositions
US17/384,227 Pending US20210346503A1 (en) 2012-09-11 2021-07-23 Colon cleansing compositions and method of use

Family Applications After (8)

Application Number Title Priority Date Filing Date
US14/223,127 Active US8999313B2 (en) 2012-09-11 2014-03-24 Compositions
US14/657,495 Active US9326969B2 (en) 2012-09-11 2015-03-13 Compositions
US14/954,290 Abandoned US20160184263A1 (en) 2012-09-11 2015-11-30 Compositions
US15/141,054 Active 2033-10-19 US9707297B2 (en) 2012-09-11 2016-04-28 Compositions
US15/454,132 Active US10016504B2 (en) 2012-09-11 2017-03-09 Compositions
US15/605,617 Active 2033-09-15 US10918723B2 (en) 2012-09-11 2017-05-25 Colon cleansing compositions and methods of use
US16/028,819 Abandoned US20180311361A1 (en) 2012-09-11 2018-07-06 Compositions
US17/384,227 Pending US20210346503A1 (en) 2012-09-11 2021-07-23 Colon cleansing compositions and method of use

Country Status (33)

Country Link
US (9) US20140186470A1 (es)
EP (2) EP2895163B1 (es)
JP (3) JP6655391B2 (es)
KR (5) KR20170098980A (es)
CN (2) CN105007915B (es)
AR (1) AR092500A1 (es)
AU (2) AU2013314442C1 (es)
BR (1) BR112015005270B1 (es)
CA (2) CA3116204C (es)
CY (1) CY1121668T1 (es)
DK (2) DK3473248T3 (es)
EA (1) EA028866B1 (es)
ES (3) ES2909386T3 (es)
HK (1) HK1206604A1 (es)
HR (1) HRP20191007T1 (es)
HU (1) HUE043605T2 (es)
IL (2) IL237377B (es)
IN (1) IN2015DN01704A (es)
LT (1) LT2895163T (es)
ME (1) ME03413B (es)
MX (2) MX359318B (es)
MY (2) MY174758A (es)
NL (1) NL2011424C2 (es)
NZ (2) NZ743984A (es)
PL (2) PL3473248T3 (es)
PT (2) PT3473248T (es)
RS (1) RS58979B1 (es)
SG (4) SG11201501713XA (es)
SI (1) SI2895163T1 (es)
TW (2) TWI687238B (es)
UA (1) UA116546C2 (es)
WO (1) WO2014040994A1 (es)
ZA (2) ZA201501415B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189444A1 (en) * 2016-01-06 2017-07-06 California Institute Of Technology Polymeric compositions and related systems and methods for regulating biological hydrogels
CN111670039A (zh) * 2018-02-01 2020-09-15 株式会社泰俊制药 肠清洁组合物
EP4084869A4 (en) * 2019-12-30 2024-02-14 Orion Innovations Inc COMPOSITION AND THERAPY FOR THE TREATMENT OF NAUSEA REFLEXES

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (zh) * 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
KR20170098980A (ko) * 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
EA201992382A3 (ru) 2013-03-15 2020-05-31 Брейнтри Лабораторис, Инк. Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
MY188550A (en) * 2014-03-10 2021-12-21 Norgine Bv Method of cleansing the colon
FR3049464B1 (fr) * 2016-03-29 2021-08-06 Marc Girard Preparations coliques
WO2019151829A1 (ko) * 2018-02-01 2019-08-08 주식회사태준제약 장세척 조성물
JP7011629B2 (ja) * 2019-07-11 2022-01-26 ノージン ビーブイ 結腸を洗浄する方法
CN110339158B (zh) * 2019-08-21 2020-11-13 扬子江药业集团上海海尼药业有限公司 一种硫酸钠钾镁口服溶液及其制备方法
KR20220033790A (ko) * 2020-09-10 2022-03-17 강윤식 장 정결용 조성물
WO2022182173A1 (ko) * 2021-02-26 2022-09-01 주식회사태준제약 장세척을 위한 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
US20100297263A1 (en) * 2002-10-25 2010-11-25 Norgine Bv Colon cleansing compositions and methods

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2187467A (en) 1939-02-11 1940-01-16 Lilly Co Eli Cevitamate solution
US2427692A (en) 1940-07-29 1947-09-23 Frances R Ruskin Therapeutic metal cevitamate compositions
US2481353A (en) 1946-10-25 1949-09-06 Schnabel Lewis Wilson Method of manufacturing vitamin concentrates
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
US3211614A (en) 1963-07-10 1965-10-12 Pharmacia Ab Enema-type laxative composition
AU6196786A (en) 1985-08-01 1987-03-05 Braintree Laboratories Inc. Low-sodium laxative and lavage formulation
JPS6295194A (ja) 1985-10-18 1987-05-01 Sekisui Chem Co Ltd ミネラルウオ−タ−製造剤
JP2557111Y2 (ja) 1986-07-11 1997-12-08 富士電機株式会社 自動販売機の商品収納棚における商品残量表示装置
DE3807712A1 (de) 1987-07-25 1989-02-02 Nordend Apotheke Angela Hein Arzneimittel-trockenpraeparat zur bereitung einer laxativ wirkenden trinkloesung sowie ein verfahren zur herstellung dieses praeparates
JPH01125319A (ja) 1987-11-11 1989-05-17 Morishita Seiyaku Kk 全腸管洗浄液用投与組成物
JP2596764B2 (ja) 1987-11-18 1997-04-02 ルセル森下株式会社 腸管洗浄液剤
EP0397689B1 (en) * 1987-12-24 1994-05-11 BORODY, Thomas Julius Orthostatic lavage solutions
JP2630423B2 (ja) 1988-05-06 1997-07-16 富山化学工業株式会社 低ナトリウム塩味料
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
SE465669B (sv) 1988-07-15 1991-10-14 Hanson & Moehring Ab Salt foer livsmedelsaendamaal samt foerfarande foer dess framstaellning
JPH0263042A (ja) 1988-08-30 1990-03-02 Fuji Photo Film Co Ltd 放射線画像情報記録読取装置
JP2936168B2 (ja) 1988-12-27 1999-08-23 東ソー株式会社 ポリオレフィンの製造法
US5540945A (en) 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
JP2557111B2 (ja) 1989-11-27 1996-11-27 フジックス 株式会社 高濃度のマグネシウム溶液の製造方法及びそれによって得られたマグネシウム溶液並びにその用途
FR2662442A1 (fr) 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
JPH04112830A (ja) 1990-08-31 1992-04-14 Morishita Pharmaceut Co Ltd 腸管洗浄液用組成物の製造法
JP3457012B2 (ja) 1992-01-14 2003-10-14 富士化学工業株式会社 非晶質クエン酸マグネシウム顆粒物質及びその製造法
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
JPH06295194A (ja) 1993-04-08 1994-10-21 Matsushita Electric Ind Co Ltd 信号比較装置
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
JP3439559B2 (ja) 1995-02-01 2003-08-25 三栄源エフ・エフ・アイ株式会社 食品の風味向上法
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
CN1150021A (zh) 1996-01-11 1997-05-21 李智军 清肠剂
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
JP4092748B2 (ja) 1997-09-05 2008-05-28 ニプロ株式会社 腸管洗浄液
JPH11228423A (ja) 1998-02-17 1999-08-24 Ohara Yakuhin Kogyo Kk 腸管洗浄液用組成物
CN1093259C (zh) 1998-04-29 2002-10-23 宝山钢铁股份有限公司 乳化液皂化值和杂油含量的测定方法
CZ9900555A3 (cs) 1999-02-19 2000-10-11 Radomír Ing. Špetík Způsob mimotělní identifikace maligního a jiného onemocnění lidí a směs látek jako stimulantu krve
US6444198B1 (en) 1999-02-22 2002-09-03 Smithkline Beecham Corporation Effervescent laxatives
AUPQ847000A0 (en) 2000-06-29 2000-07-27 Adventures Plus Pty Ltd Nutrient beverage
SE518524C2 (sv) 2000-12-21 2002-10-22 Vaederstad Verken Ab Regleranordning för en jordbruksmaskin
JP2002207002A (ja) 2001-01-10 2002-07-26 Hitachi Eng Co Ltd 大気環境シミュレーションシステム
CN1143678C (zh) 2001-02-23 2004-03-31 东北制药总厂 Vc－磷酸酯镁在制备治疗便秘药物中的应用
JP2002265372A (ja) 2001-03-07 2002-09-18 Shimizu Pharmaceutical Co Ltd 腸管洗浄製剤
RU2178292C1 (ru) 2001-04-13 2002-01-20 Государственный научный центр колопроктологии Министерства здравоохранения и медицинской промышленности РФ Средство для общего промывания желудочно-кишечного тракта
JP5041642B2 (ja) 2001-08-30 2012-10-03 日本製薬株式会社 経口腸管洗浄液用組成物及び経口腸管洗浄液用充填製剤
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
ATE477790T1 (de) 2001-10-29 2010-09-15 Ajinomoto Kk Lösung zur darmreinigung
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
DE10239161A1 (de) 2002-08-27 2004-03-11 Ludwig Kraemer Verwendung einer Vitamin C und Magnesium entahltenden Zusammensetzung zur Anregung der Darmtätigkeit
CA2503956A1 (en) 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
JP2004323479A (ja) 2003-04-28 2004-11-18 Ajinomoto Co Inc 便秘用緩下剤
JP2004323456A (ja) 2003-04-28 2004-11-18 Shimizu Pharmaceutical Co Ltd 腸管洗浄製剤
US20050152989A1 (en) 2003-07-09 2005-07-14 Braintree Laboratories, Inc. Method for treating irritable bowel syndrome
WO2005049049A1 (en) 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
US20050226906A1 (en) 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
GB0409104D0 (en) 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
AU2004320512A1 (en) 2004-06-04 2005-12-22 Braintree Laboratories, Inc. Method of bowel cleansing
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
CA2607250C (en) 2005-05-06 2012-11-06 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
WO2007037803A2 (en) 2005-09-16 2007-04-05 Eli Ehrenpreis Water-soluble colonoscopy lubricant
CN1813674A (zh) 2005-12-12 2006-08-09 王冕 一种用于静脉给药的维生素c钠制剂及其制备方法
CN100476462C (zh) 2006-06-20 2009-04-08 刘彤 反射镜基体及其制造方法
US8129430B2 (en) 2007-08-31 2012-03-06 C.B. Fleet Company, Inc. Method of reducing phosphate nephropathy in a mammal
US20100297264A1 (en) 2007-10-17 2010-11-25 Thomas Jefferson University Bowel purgative and uses thereof
DE102007052870A1 (de) 2007-11-02 2009-05-07 Sasol Germany Gmbh Verwendung von Polyethylenglykol-Pulvern und Zusammensetzungen enthaltend diese
CN101450074B (zh) 2007-11-30 2012-03-14 凌沛学 一种明显改善胃肠道功能、防治便秘的组合物
CN101496589A (zh) 2008-01-29 2009-08-05 北京康必得药业有限公司 膳食纤维咀嚼片剂
US20090232943A1 (en) 2008-03-12 2009-09-17 Aly Gamay Stabilized vitamin solutions; use thereof; process for their production; and formulations comprising the same
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
CN101766563A (zh) 2008-12-29 2010-07-07 山东北大高科华泰制药有限公司 一种水溶性维生素注射剂与氯化钠注射液的配合使用方法
US20100178360A1 (en) 2009-01-13 2010-07-15 Universite Libre De Bruxelles Nutritive composition
US20100255122A1 (en) * 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
US8778306B2 (en) 2009-04-21 2014-07-15 Dale R. Bachwich Colon lavage system
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
GB0912487D0 (en) * 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
AU2011101324B4 (en) 2009-07-17 2012-01-19 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
DK2322190T3 (da) * 2009-11-02 2013-06-10 Promefarm S R L Sammensætninger til tarmrensning og anvendelse deraf
CN101766648B (zh) 2010-03-02 2012-01-11 舒泰神（北京）生物制药股份有限公司 聚乙二醇电解质颗粒制剂及其制造方法
AU2011226324B2 (en) 2010-03-10 2015-09-24 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
GB201018650D0 (en) 2010-11-04 2010-12-22 Norgine Bv Methods and compositions
MX342181B (es) 2010-11-04 2016-09-20 Norgine Bv Formulaciones que comprenden polietilenglicol.
DE202010016398U1 (de) 2010-12-09 2011-04-28 Norgine B.V. Verbesserungen bei pharmazeutischen Zusammensetzungen und bezüglich pharmazeutischer Zusammensetzungen
BR112013019360A2 (pt) * 2011-01-28 2017-03-28 A Shaver William ingredientes, componente seco de formulação oral de baixo teor de cloreto farmaceuticamente aceitável para limpeza de cólon, solução de base de reposição de eletrólito aquosa para uso em lavagem colônica, métodos para limpar os intestinos de paciente, para preparar solução aquosa para limpeza do cólon e para aumentar substancialmente o paladar de limpador de cólon e kits para evacuação do cólon.
EP2671562A4 (en) 2011-01-31 2016-01-20 Ajinomoto Kk MORE CHAMBER CONTAINER
KR101852502B1 (ko) 2011-01-31 2018-04-26 노어긴 비.브이. 조성물에 관한 개선
GB201103942D0 (en) 2011-03-08 2011-04-20 Norgine Bv Compositions
TWI535461B (zh) * 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
JP5708141B2 (ja) 2011-03-30 2015-04-30 味の素株式会社 経口投与用液剤を調製するための経口投与用製剤
WO2013001315A1 (en) 2011-06-30 2013-01-03 Zernicka-Goetz Magdalena Dorota Materials and methods for cell culture
US10226238B2 (en) 2011-09-12 2019-03-12 Creatics Llc Non-invasive methods of detecting target molecules
US20130102661A1 (en) 2011-10-25 2013-04-25 The Chinese University Of Hong Kong Irrigation solutions containing ascorbic acid or its salts and use thereof
BR112014009946A2 (pt) 2011-10-27 2017-04-25 Salix Pharmaceuticals Inc "composição, composição farmacêutica ou formulação purgativas e uso das mesmas"
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
DK2787982T3 (da) 2011-12-07 2023-03-27 Msm Innovations Inc Sammensætning til tarmpræparat
US20130156871A1 (en) 2011-12-20 2013-06-20 Water Pik, Inc. Nasal Wash Solution
CN102600201B (zh) 2012-02-07 2014-07-16 舒泰神（北京）生物制药股份有限公司 用于通便和清肠的药物组合物及其制备方法
KR101210831B1 (ko) 2012-02-10 2012-12-11 주식회사태준제약 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물
CN102805753B (zh) 2012-08-20 2014-09-24 深圳万和制药有限公司 包含聚乙二醇和电解质的药物组合物
CN102805752B (zh) 2012-08-20 2014-04-02 深圳万和制药有限公司 复方聚乙二醇电解质散及其制备方法
CN102772427B (zh) 2012-08-20 2014-02-05 深圳万和制药有限公司 一种复方聚乙二醇电解质组合物
KR20170098980A (ko) * 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
CN103550212A (zh) 2013-11-03 2014-02-05 王显著 含匹可硫酸和抗坏血酸的药物组合物
CN103550249B (zh) 2013-11-09 2015-08-12 王显著 一种用于肠道准备的药物组合物
JP6295194B2 (ja) 2014-12-22 2018-03-14 エルジー ディスプレイ カンパニー リミテッド 電子部品の実装方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297263A1 (en) * 2002-10-25 2010-11-25 Norgine Bv Colon cleansing compositions and methods
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189444A1 (en) * 2016-01-06 2017-07-06 California Institute Of Technology Polymeric compositions and related systems and methods for regulating biological hydrogels
CN111670039A (zh) * 2018-02-01 2020-09-15 株式会社泰俊制药 肠清洁组合物
EP4084869A4 (en) * 2019-12-30 2024-02-14 Orion Innovations Inc COMPOSITION AND THERAPY FOR THE TREATMENT OF NAUSEA REFLEXES

Also Published As

Publication number Publication date
JP2015527385A (ja) 2015-09-17
US20170173156A1 (en) 2017-06-22
JP6557675B2 (ja) 2019-08-07
CN105007915B (zh) 2018-09-28
PT3473248T (pt) 2022-03-30
US9326969B2 (en) 2016-05-03
ES2728459T3 (es) 2019-10-24
AR092500A1 (es) 2015-04-22
KR20230010844A (ko) 2023-01-19
JP2020073579A (ja) 2020-05-14
PT2895163T (pt) 2019-06-14
EP3473248A1 (en) 2019-04-24
US20160184263A1 (en) 2016-06-30
US20180311361A1 (en) 2018-11-01
CY1121668T1 (el) 2020-07-31
AU2013314442C1 (en) 2018-10-11
US20210346503A1 (en) 2021-11-11
JP6655391B2 (ja) 2020-02-26
EP3473248B1 (en) 2022-01-05
ES2831412T3 (es) 2021-06-08
CN105007915A (zh) 2015-10-28
MX359318B (es) 2018-09-25
SG11201501713XA (en) 2015-04-29
AU2013314442B2 (en) 2018-04-19
EP2895163A1 (en) 2015-07-22
WO2014040994A1 (en) 2014-03-20
CA3116204A1 (en) 2014-03-20
IL237377A0 (en) 2015-04-30
JP7277396B2 (ja) 2023-05-18
US10016504B2 (en) 2018-07-10
NZ743984A (en) 2019-10-25
KR102257207B1 (ko) 2021-05-31
KR20210063445A (ko) 2021-06-01
MY174758A (en) 2020-05-13
RS58979B1 (sr) 2019-08-30
HUE043605T2 (hu) 2019-08-28
TW201416092A (zh) 2014-05-01
CN106102738A (zh) 2016-11-09
AU2018204694A1 (en) 2018-07-19
KR20150054990A (ko) 2015-05-20
ES2909386T3 (es) 2022-05-06
KR101771586B1 (ko) 2017-08-25
BR112015005270A8 (pt) 2019-08-13
NL2011424C2 (en) 2015-03-12
IL269024A (en) 2019-10-31
US8999313B2 (en) 2015-04-07
EA028866B1 (ru) 2018-01-31
MX2016011256A (es) 2016-11-15
IL237377B (en) 2019-09-26
KR20190137925A (ko) 2019-12-11
SG10202112138QA (en) 2021-12-30
MY193378A (en) 2022-10-07
MX2015003031A (es) 2015-06-10
PL2895163T3 (pl) 2019-10-31
BR112015005270B1 (pt) 2022-11-01
SG10201807427RA (en) 2018-09-27
TWI687238B (zh) 2020-03-11
CA2884472C (en) 2021-06-22
NZ705499A (en) 2018-07-27
UA116546C2 (uk) 2018-04-10
ME03413B (me) 2020-01-20
US20160235854A1 (en) 2016-08-18
US20150182501A1 (en) 2015-07-02
AU2018204694C1 (en) 2020-04-09
HRP20191007T1 (hr) 2019-08-23
JP2017507965A (ja) 2017-03-23
AU2013314442A1 (en) 2015-03-26
CA3116204C (en) 2023-09-12
DK2895163T3 (da) 2019-06-03
BR112015005270A2 (pt) 2017-07-04
AU2018204694B2 (en) 2019-09-26
ZA201603747B (en) 2022-09-28
SI2895163T1 (sl) 2019-07-31
EP2895163B1 (en) 2019-03-06
EA201500320A1 (ru) 2015-06-30
PL3473248T3 (pl) 2022-07-25
ZA201501415B (en) 2017-09-27
TWI756623B (zh) 2022-03-01
KR20170098980A (ko) 2017-08-30
LT2895163T (lt) 2019-06-25
IN2015DN01704A (es) 2015-05-22
CA2884472A1 (en) 2014-03-20
US20140228432A1 (en) 2014-08-14
SG10201702005VA (en) 2017-04-27
HK1206604A1 (en) 2016-01-15
DK3473248T3 (da) 2022-04-04
US20170258919A1 (en) 2017-09-14
TW202017562A (zh) 2020-05-16
US10918723B2 (en) 2021-02-16
US9707297B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
US10918723B2 (en) Colon cleansing compositions and methods of use
AU2015228962B2 (en) Method of cleansing the colon
NZ723017B2 (en) Method of cleansing the colon
IES20130273A2 (en) Compositions comprising PEG and ascorbate

Legal Events

Date Code Title Description
AS Assignment

Owner name: NORGINE BV, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CLAYTON, LUCY;COCKETT, ALASDAIR;CHRISTODOULOU, MARK;AND OTHERS;SIGNING DATES FROM 20130816 TO 20130910;REEL/FRAME:032829/0027

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NORGINE BV, NETHERLANDS

Free format text: CHANGE OF ADDRESS;ASSIGNOR:NORGINE BV;REEL/FRAME:047443/0213

Effective date: 20180820